<PAGE> 1
Filed pursuant to Rule 424(b)(1)
Registration No. 333-13455
PROSPECTUS
dated November 18, 1996
1,850,000 SHARES
SEAMED
Corporation
COMMON STOCK
Of the 1,850,000 shares of Common Stock offered hereby, 1,529,720 shares are
being sold by SeaMED Corporation ("SeaMED" or the "Company") and 320,280 shares
are being sold by the selling shareholders (the "Selling Shareholders"). The
Company will not receive any proceeds from the sale of shares by the Selling
Shareholders. See "Principal and Selling Shareholders."
Prior to this offering, there has been no public market for the Common Stock of
the Company. See "Underwriting" for a discussion of the factors considered in
determining the initial public offering price. The Common Stock has been
approved for listing on the Nasdaq National Market, upon completion of this
offering, under the symbol "SEMD."
SEE "RISK FACTORS" BEGINNING ON PAGE 5 FOR A DISCUSSION OF CERTAIN FACTORS THAT
SHOULD BE CONSIDERED BY PROSPECTIVE INVESTORS.
THESE SECURITIES HAVE NOT BEEN APPROVED OR DISAPPROVED BY THE SECURITIES AND
EXCHANGE COMMISSION OR ANY STATE SECURITIES COMMISSION NOR HAS THE SECURITIES
AND EXCHANGE COMMISSION OR ANY STATE SECURITIES COMMISSION PASSED UPON THE
ACCURACY OR ADEQUACY OF THIS PROSPECTUS. ANY REPRESENTATION TO THE CONTRARY IS A
CRIMINAL OFFENSE.
<TABLE>
<CAPTION>
=======================================================================================================
Proceeds to
Price to Underwriting Proceeds to Selling
Public Discount(1) Company(2) Shareholders
<S> <C> <C> <C> <C>
- -------------------------------------------------------------------------------------------------------
Per Share.............................. $11.00 $0.77 $10.23 $10.23
- -------------------------------------------------------------------------------------------------------
Total(3)............................... $20,350,000 $1,424,500 $15,649,035 $3,276,465
=======================================================================================================
</TABLE>
(1) The Company and the Selling Shareholders have agreed to indemnify the
Underwriters against certain liabilities, including liabilities under the
Securities Act of 1933, as amended. See "Underwriting."
(2) Before deducting expenses payable by the Company estimated at $850,000.
(3) The Company has granted the Underwriters a 30-day option to purchase up to
an additional 277,500 shares of Common Stock solely to cover
over-allotments, if any, at the Price to Public less the Underwriting
Discount. If all such shares are purchased, the total Price to Public,
Underwriting Discount and Proceeds to Company will be $23,402,500,
$1,638,175 and $18,487,860, respectively. See "Underwriting."
The shares of Common Stock are offered by the Underwriters subject to prior sale
when, as, and if delivered and accepted by the Underwriters and subject to their
right to reject orders in whole or in part. It is expected that certificates for
such shares will be available for delivery at the offices of Piper Jaffray Inc.
in Minneapolis, Minnesota on or about November 22, 1996.
PIPER JAFFRAY INC. NEEDHAM & COMPANY, INC.
<PAGE> 2
[PHOTOGRAPHS]
Photograph Caption
Photograph of Stem Cell Separator Stem Cell Separator,
CellPro, Incorporated
Photograph of Company Headquarters 14500 N.E. 87th Street,
Redmond, Washington
Photograph of Drive Console Drive Console, Boston Scientific
Corporation
Photograph of Transurethral Transurethral Thermal Therapy
Thermal Therapy System System, Urologix, Inc.
Photograph of Control Console for Control Console for Cardioplegia
Cardioplegia System System, Sorin Biomedical, Inc.
Photograph of RF Generator RF Generator, Boston Scientific
Corporation
Photograph of Personal Hemodialysis Personal Hemodialysis System,
System Aksys Ltd.
------------------------
IN CONNECTION WITH THIS OFFERING, THE UNDERWRITERS MAY OVER-ALLOT OR EFFECT
TRANSACTIONS WHICH STABILIZE OR MAINTAIN THE MARKET PRICE OF THE COMMON STOCK
OFFERED HEREBY AT A LEVEL ABOVE THAT WHICH MIGHT OTHERWISE PREVAIL IN THE OPEN
MARKET. SUCH TRANSACTIONS MAY BE EFFECTED ON THE NASDAQ NATIONAL MARKET, IN THE
OVER-THE-COUNTER MARKET OR OTHERWISE. SUCH STABILIZING, IF COMMENCED, MAY BE
DISCONTINUED AT ANY TIME.
------------------------
This Prospectus includes trade names, trademarks and registered trademarks
of companies other than SeaMED.
With the exception of Boston Scientific Corporation's RF Generator, which
represented 7.1% of the Company's total revenues in fiscal year 1996, none of
the products pictured above generated more than 5% of such revenues. The Company
has ongoing contracts with respect to each pictured product, other than Sorin
Biomedical Inc.'s control console and Boston Scientific Corporation's RF
Generator.
2
<PAGE> 3
PROSPECTUS SUMMARY
The following summary is qualified in its entirety by, and should be read
in conjunction with, the more detailed information and the Financial Statements
and Notes thereto appearing elsewhere in this Prospectus. Unless otherwise
noted, all information in this Prospectus, including financial information,
share data and per share data (i) reflects the pro forma conversion into shares
of Common Stock of all outstanding shares of the Company's convertible
redeemable preferred stock (the "Preferred Stock") upon the closing of this
offering, (ii) reflects the pro forma accrual of cumulative dividends on Class A
and D Preferred Stock, and (iii) assumes no exercise of the Underwriters'
over-allotment option. See "Underwriting." The Company's fiscal year consists of
the 52/53-week period that ends on the Thursday nearest to June 30. For
convenience of presentation, all fiscal periods in this Prospectus are shown as
ending on a calendar month-end.
THE COMPANY
SeaMED Corporation (the "Company" or "SeaMED") manufactures advanced
durable electronic medical instruments for medical technology companies, often
as part of systems that also include single-use components. To assist its
customers in developing and commercializing their instruments for manufacture by
SeaMED, the Company provides a wide range of engineering services and regulatory
expertise. In its last fiscal year, SeaMED manufactured or engineered
instruments for many established and emerging medical technology companies.
SeaMED's revenues have grown from $8.7 million in fiscal year 1992 to $26.1
million in fiscal year 1996, a compound annual growth rate of 32%, and its
operating income has grown from $807,000 in fiscal year 1992 to $2.1 million in
fiscal year 1996, a compound annual growth rate of 27%. During this period, the
number of manufactured instruments grew from seven to 23.
Since 1988, SeaMED has focused its business primarily on manufacturing
medical instruments and believes it is the largest independent manufacturer of
advanced medical instruments for medical technology companies. As part of its
growth strategy, SeaMED continues to expand its engineering expertise,
regulatory knowledge and manufacturing capabilities, thereby allowing it to
design and manufacture a broader range of medical instruments. During the fourth
quarter of fiscal year 1996, SeaMED began manufacturing a nonmedical product for
Coinstar, Inc., which accounted for $1.8 million and $2.5 million of SeaMED's
revenues in the fourth quarter of fiscal year 1996 and the first quarter of
fiscal year 1997, respectively.
The demand for health care has grown rapidly in recent years, including
demand for medical instruments that can lessen the overall cost of health care
while improving patient outcomes. As medical instruments have incorporated the
latest developments in computers, electronics, materials and other technologies,
and medical technology companies have sought to comply with increasingly
stringent regulatory requirements, the cost of product development and the
length of the development cycle have increased substantially. The risks in
developing and launching new medical products also have increased significantly
as competition in the highly fragmented medical technology industry has
increased. As a result, many medical technology companies increasingly are
focusing their resources on certain critical functions and outsourcing others.
SeaMED believes that the trend toward outsourcing engineering and manufacturing
of durable medical instruments is in its early stages and will expand
significantly.
SeaMED provides complete solutions to meet its customers' needs for
instrument engineering, prototyping, preproduction and volume manufacturing.
SeaMED offers its customers the following advantages:
- Broad experience in product development, engineering, manufacturing
and regulatory compliance for advanced medical instruments
- Reduction of fixed capital and personnel commitments for noncore
functions
- Demand-driven production flexibility
- In-place resources to shorten time-to-market
- FDA and ISO 9001 compliant manufacturing facilities
- Integrated engineering and manufacturing, improving quality and
reducing costs
SeaMED, a Washington corporation, was formed in 1976. SeaMED's executive
offices are located at 14500 Northeast 87th Street, Redmond, Washington 98052
and its telephone number is (206) 867-1818.
3
<PAGE> 4
THE OFFERING
<TABLE>
<S> <C>
Common Stock offered by the Company.............. 1,529,720 shares
Common Stock offered by the Selling
Shareholders................................... 320,280 shares
Common Stock to be outstanding after this
offering....................................... 5,136,906 shares(1)
Use of proceeds.................................. Repayment of outstanding bank
indebtedness, expected to be between $3.5
million and $5.0 million, payment of
approximately $1.8 million for cumulative
dividends on Preferred Stock, to fund
working capital needs and for general
corporate purposes. See "Use of Proceeds."
Nasdaq National Market symbol.................... SEMD
</TABLE>
SUMMARY FINANCIAL DATA
(in thousands, except per share amounts)
<TABLE>
<CAPTION>
QUARTER
YEAR ENDED JUNE 30, ENDED SEPTEMBER 30,
------------------------------- -------------------
1994 1995 1996 1995 1996
------- ------- ------- ------- -------
<S> <C> <C> <C> <C> <C>
STATEMENT OF INCOME DATA:
Revenues................................. $14,720 $17,661 $26,130 $ 5,000 $10,076
Cost of sales............................ 11,965 14,590 21,093 4,207 8,391
Gross margin............................. 2,755 3,071 5,037 793 1,685
Marketing, general and administrative
expenses............................... 1,818 1,931 2,937 491 847
Operating income......................... 937 1,140 2,100 302 838
Net income............................... $ 1,007 $ 775 $ 1,240 $ 167 $ 487
======= ======= ======= ======= =======
Net income per share data(2):
Primary................................ $ 0.39 $ 0.25 $ 0.42 $ 0.04 $ 0.17
======= ======= ======= ======= =======
Fully diluted.......................... $ 0.30 $ 0.21 $ 0.32 $ 0.04 $ 0.12
======= ======= ======= ======= =======
</TABLE>
<TABLE>
<CAPTION>
SEPTEMBER 30, 1996
--------------------------
PRO FORMA AS ADJUSTED(3)
--------- --------------
<S> <C> <C>
BALANCE SHEET DATA:
Working capital...................................................... $ 3,747 $ 17,627
Total assets......................................................... 16,538 25,994
Notes payable to bank................................................ 2,246 --
Long-term debt, including current portion............................ 2,119 751
Total shareholders' equity........................................... 5,270 20,069
</TABLE>
- ---------------
(1) Based on shares outstanding at September 30, 1996. Excludes 529,265 shares
of Common Stock issuable upon exercise of stock options and a warrant
outstanding at such date, which had a weighted average exercise price of
$2.56 per share. Also excludes 96,418 shares reserved for issuance pursuant
to future option grants under the Company's stock option plans. See
"Management -- Stock Plans" and "Description of Capital Stock."
(2) See Note 1 of Notes to Financial Statements for an explanation of the number
of shares used in computing net income per share.
(3) As adjusted to reflect the sale by the Company of 1,529,720 shares of Common
Stock offered hereby and the application of the estimated net proceeds
therefrom. See "Use of Proceeds."
4
<PAGE> 5
RISK FACTORS
In addition to the other information contained in this Prospectus, the
following risk factors should be considered carefully in evaluating the Company
and its business before purchasing shares of Common Stock offered by this
Prospectus. This Prospectus contains, in addition to historical information,
forward-looking statements that involve risks and uncertainties. The Company's
actual results could differ materially from the results discussed in the
forward-looking statements. Factors that could cause or contribute to such
differences include those discussed below, as well as those discussed elsewhere
in this Prospectus.
CUSTOMER RISK FACTORS
SeaMED's success depends on the success of its customers and their
instruments manufactured by SeaMED. Any unfavorable developments or adverse
effects on the sales of those products or its customers' businesses, results of
operations or financial condition could have a corresponding adverse effect on
SeaMED. SeaMED believes that its customers and their products (and, accordingly,
SeaMED) are generally subject to the following risks:
Competitive Environment
The medical products industry is highly competitive and subject to
significant technological change, and requires ongoing investment to keep pace
with technological developments and quality and regulatory requirements. The
medical products industry consists of numerous companies, ranging from start-up
to well-established companies. Many of SeaMED's customers have a limited number
of products, and some market only a single product. As a result, any adverse
development with respect to these customers' products may have a material
adverse effect on the business and financial condition of such customer, which
may adversely affect that customer's ability to purchase and pay for its
products manufactured by the Company. The competitors and potential competitors
of SeaMED's customers may succeed in developing or marketing technologies and
products that will be more accepted in the marketplace than the instruments
manufactured by SeaMED for its customers or that would render its customers'
technology and products obsolete or noncompetitive. In addition, other
competitors may develop alternative treatments or cures so that the need for the
instruments manufactured by SeaMED could be reduced or eliminated. Many of
SeaMED's customers are emerging medical technology companies that have
competitors and potential competitors with substantially greater capital
resources, research and development staffs and facilities and substantially
greater experience in developing new products, obtaining regulatory approvals
and manufacturing and marketing medical products. At September 30, 1996,
approximately 10 customers, representing 38.8% of SeaMED's revenues in fiscal
year 1996, were emerging medical technology companies. SeaMED's customers may
not be successful in launching and marketing their products, or may not respond
to pricing, marketing or other competitive pressures or the rapid technological
innovation demanded by the marketplace and, as a result, may experience a
dramatic drop in product sales, which would have an adverse effect on the
Company's business, results of operations and financial condition. See
"Business -- Industry Overview."
Customer Regulatory Compliance
The Food and Drug Administration (the "FDA") regulates instruments
manufactured by SeaMED under the Federal Food, Drug, and Cosmetic Act, as
amended (the "FDC Act"), which requires certain clearances or approvals from the
FDA before new medical devices can be marketed. As a prerequisite to any
introduction of a new device into the medical marketplace, SeaMED's customers
must obtain necessary product clearances or approvals from the FDA or other
regulatory agencies with applicable jurisdiction. There can be no assurance that
SeaMED's customers will obtain such clearances or approvals on a timely basis,
if at all.
Certain medical instruments manufactured by SeaMED may be subject to the
need to obtain FDA approval of a premarket approval application ("PMA"), which
requires substantial preclinical and clinical testing and may cause delays and
prevent introduction of such instruments. Currently, nine of SeaMED's customers
are seeking or plan to seek PMA approval for instruments to be manufactured by
SeaMED. Other
5
<PAGE> 6
instruments can be marketed only by establishing "substantial equivalence" to a
predicate device in a 510(k) premarket notification. FDA marketing approval and
clearance regulations depend heavily on administrative interpretations, which
may change retroactively and may create additional barriers that prevent or
delay the introduction of a product. Marketing approval for PMA products could
be denied altogether if clinical testing does not establish that the product is
safe and effective. Clinical testing must be performed in accordance with the
FDA's regulations. A customer's failure to comply with the FDA's requirements
can result in the delay or denial of its PMA. Delays in obtaining PMA approval
are frequent, and, in turn, could result in delaying or canceling customer
orders from SeaMED. Many products never receive PMA approval. Once FDA approval
is obtained, a new approval, in the form of a PMA supplement, may be needed to
modify the device, its intended use, or its manufacturing. A 510(k) premarket
notification may also need to contain clinical data. 510(k) clearance may be
delayed, and, in some instances, 510(k) clearance is never obtained. Once a
product is in commercial distribution, discovery of product problems or failure
to comply with regulatory standards may result in restrictions on the product's
future use or withdrawal of the product from the market despite prior
governmental approval. In 1991, one of the Company's customers recalled its
disposable product, and postponed all purchases of the related instrument from
SeaMED, which had an adverse effect on the Company's results of operations.
There can be no assurance that product recalls, product defects or loss of
necessary regulatory approvals will not occur in the future. The delays and
potential product cancellations inherent in the development, regulatory
approval, commercialization and ongoing regulatory compliance of instruments
manufactured by the Company may have a material adverse effect on the Company's
business, reputation, results of operations and financial condition.
Sales of SeaMED-manufactured medical instruments outside the United States
are subject to regulatory requirements that vary widely from country to country.
The time required to obtain approval for sale in foreign countries may be longer
or shorter than that required for FDA approval, and the requirements may differ.
The FDA also regulates the sale of exported medical devices, although to a
lesser extent than devices sold in the United States. For medical products
exported to countries in the European Community, SeaMED's customers will want
their products to qualify for distribution under the "CE mark," which
qualification enables certain medical products to move freely within the
European Community. Commencing in 1998, medical product manufacturers will be
required to obtain certifications necessary to enable the CE mark to be affixed
to medical products they manufacture for sale throughout the European Community.
In addition, SeaMED's customers must comply with other laws generally applicable
to foreign trade, including technology export restrictions, tariffs and other
regulatory barriers. There can be no assurance that SeaMED's customers will
obtain all required clearances or approvals for exported products on a timely
basis, if at all. Failure or delay in obtaining the requisite regulatory
approvals for exported instruments manufactured by the Company may have an
adverse effect on the Company's business, results of operations and financial
condition.
Medical instruments manufactured by SeaMED and marketed by its customers
pursuant to FDA clearances or approvals are subject to pervasive and continuing
regulation by the FDA and certain state and foreign regulatory agencies.
Regulatory approvals may include significant limitations on the indicated uses
for which the product may be marketed. FDA enforcement policy prohibits the
marketing of approved medical products for unapproved uses. The Company's
customers control the marketing of their products, including representing to the
market the approved uses of their products. If a customer engages in prohibited
marketing practices, the FDA or another regulatory agency with applicable
jurisdiction could intervene, possibly resulting in marketing restrictions,
including prohibitions on further product sales, or civil or criminal penalties,
which could have an adverse effect on the Company's business, results of
operations and financial condition.
Changes in existing laws and regulations or policies could affect adversely
the ability of the Company's customers to comply with regulatory requirements.
Failure to comply with regulatory requirements could have a material adverse
effect on a customer's business, results of operations and financial condition,
which, in turn, could affect adversely the Company's business, results of
operations and financial condition. There can be no assurance that a customer of
the Company, or the Company, will not be required to incur significant costs to
comply with laws and regulations in the future or that compliance with such laws
and regulations will not have a material adverse effect on the Company's
business, results of operations and financial condition. See
"Business -- Governmental Regulation."
6
<PAGE> 7
Uncertain Market Acceptance of Products; Product Obsolescence
There can be no assurance that SeaMED's customers' products will gain any
significant market acceptance and market share among physicians, patients and
health care payors, even if required regulatory approvals are obtained. Market
acceptance may depend on a variety of factors, including educating physicians
regarding the use of a new procedure, overcoming physician objections to certain
effects of the product or its related treatment regimen, and convincing health
care payors that the benefits of the product and its related treatment regimen
outweigh its costs. Market acceptance and market share are also affected by the
timing of market introduction of competitive products. Accordingly, the relative
speed with which SeaMED's customers can develop products, gain regulatory
approval and reimbursement acceptance and supply commercial quantities of the
product to the market are expected to be important factors in market acceptance
and market share. Many of SeaMED's customers, especially emerging medical
technology companies, have limited or no experience in marketing their products
and have not made marketing or distribution arrangements for their products.
SeaMED's customers may be unable to establish effective sales and marketing and
distribution channels to successfully commercialize their products.
In addition, the marketplace for medical products is characterized by rapid
change and technological innovation. As a result, SeaMED and its customers are
subject to the risk of product obsolescence, whether from long development or
government approval cycles or the development of improved products or processes
by competitors. In addition, the marketplace could conclude that the task for
which a customer's product was designed is no longer an element of a generally
accepted diagnostic or treatment regimen. Any development adversely affecting
the market for an instrument manufactured by SeaMED would result in the
Company's having to reduce production volumes or to discontinue manufacturing
the instrument, which could have an adverse effect on the Company's business,
results of operations and financial condition. See "Business -- Industry
Overview."
Customers' Future Capital Requirements
Many of SeaMED's customers, especially emerging medical technology
companies, are not profitable and may have little or no revenues, but they have
significant working capital requirements, for which the customer may be required
to raise additional funds through public or private financings, including equity
financings. Adequate funds for their operations may not be available when
needed, if at all. Insufficient funds may require a customer to delay
development of a product, clinical trials (if required) or the commercial
introduction of the product or prevent such commercial introduction altogether.
Depending on the significance of a customer's product to SeaMED's revenues or
profitability, any adverse effect on a customer resulting from insufficient
funds could result in an adverse effect on the Company's business, results of
operations and financial condition.
Uncertainty of Third-Party Reimbursement
Sales of many of the instruments manufactured by SeaMED will be dependent
in part on availability of adequate reimbursement for those instruments from
third-party health care payors, such as government and private insurance plans,
health maintenance organizations and preferred provider organizations.
Third-party payors are increasingly challenging the pricing of medical products
and services. There can be no assurance that adequate levels of reimbursement
will be available to enable SeaMED's customers to achieve market acceptance of
their products. Without adequate support from third-party payors, the market for
the products of SeaMED's customers may be limited.
Nonmedical Customers
While SeaMED has had little experience with nonmedical customers,
nonmedical customers are subject to general business risks, such as competition,
market acceptance of their products, capital requirements and credit risks.
SeaMED's nonmedical customers operate in highly competitive industries in which
their products compete on price, quality and product enhancements and are
subject to risks of technological obsolescence. As a result, sales to nonmedical
customers may be volatile and subject to risks of cancellation. Any unfavorable
7
<PAGE> 8
development experienced by a nonmedical customer, whether of a general nature or
a specific risk not anticipated by SeaMED, could have a material adverse effect
on the Company's business, results of operations and financial condition. See
"Business -- Customers and Products."
VARIABILITY OF OPERATING RESULTS
SeaMED's annual and quarterly operating results are affected by a number of
factors, including the volume and timing of customer orders, which vary due to
(i) variation in demand for the customer's products as a result of, among other
things, product life cycles, competitive conditions and general economic
conditions, (ii) the customer's attempt to balance its inventory, (iii) the
customer's need to adapt to changing regulatory conditions and requirements, and
(iv) changes in the customer's manufacturing strategy. Under the terms of
SeaMED's contracts with its customers, SeaMED's customers have broad discretion
to control the volume and timing of instrument deliveries. In the past, changes
in customer orders have had a significant effect on SeaMED's results of
operations. Further, SeaMED's contracts with its customers typically have no
minimum purchase requirements. As a result, production may be reduced or
discontinued at any time, causing substantial sales fluctuations from quarter to
quarter or from year to year. For example, in the second quarter of fiscal year
1995, three customers delayed production of instruments from which SeaMED
expected significant revenues, one customer delayed a significant engineering
project, and the benefit from related engineering headcount reductions could not
be realized until subsequent periods. These circumstances combined to cause a
decrease in revenues from $4.5 million in the first quarter of fiscal year 1995
to $3.6 million in the second quarter of fiscal year 1995, with a corresponding
decrease in operating income from $359,000 to $54,000. Other factors that may
adversely affect SeaMED's annual and quarterly results of operations include
inexperience in manufacturing a particular instrument, inventory shortages or
obsolescence, labor costs or shortages, low gross margins on engineering
projects, an increase in engineering revenues as a percentage of total revenues,
price competition and regulatory requirements. Because SeaMED's business
organization and its related cost structure anticipate supporting a certain
minimum level of revenues, the Company's limited ability to adjust its
short-term cost structure would compound the adverse effect of any significant
revenue reduction. Any one of these factors or a combination thereof could
result in a material adverse effect on the Company's business, results of
operations and financial condition. See "Management's Discussion and Analysis of
Financial Condition and Results of Operations."
DEPENDENCE ON SMALL NUMBER OF CUSTOMERS
Historically, a substantial percentage of SeaMED's net sales have been to
fewer than 10 customers, the loss of any of which would adversely affect the
Company's business, results of operations and financial condition. In each of
the fiscal years ended June 30, 1995 and June 30, 1996, five of the Company's
customers (not all the same in each year) together represented 55% and 46% of
revenues, respectively, with Boston Scientific Corporation (through two
subsidiaries) and C. R. Bard, Inc. each accounting for more than 10% of the
Company's revenues in fiscal year 1996. If one or more of SeaMED's customers
experiences exceptional growth relative to other SeaMED customers, then SeaMED's
success could become substantially more dependent on the continued success of
such customer, and any unfavorable development regarding such customer or its
product could result in a material adverse effect on the Company's business,
results of operations and financial condition. Similarly, if one or more of
SeaMED's customers were to seek and obtain price discounts from the Company for
that customer's instruments, the resulting lower gross margins on those
instruments may have an adverse effect on the Company's overall results of
operations. In addition, if any customer with which SeaMED does a substantial
amount of business were to encounter financial distress, the customer's
unwillingness or inability to pay its obligation to the Company could result in
a material adverse effect on the Company's results of operations and financial
condition.
SeaMED's sales to Coinstar, Inc. ("Coinstar"), a nonmedical customer for
which SeaMED manufactures a coin-counting machine that exchanges loose coins for
currency, represented approximately 25% of SeaMED's revenues for the quarter
ended September 30, 1996. SeaMED currently manufactures these machines under a
nonexclusive manufacturing agreement with Coinstar that allows Coinstar to
cancel or modify orders with SeaMED on 90 days' notice. An order cancellation or
modification by Coinstar could
8
<PAGE> 9
result in an adverse effect on the Company's business, results of operations and
financial condition. See "Management's Discussion and Analysis of Financial
Condition and Results of Operations -- Results of Operations" and
"Business -- Customers and Products."
COMPETITION
SeaMED faces competition from current and prospective customers who
evaluate SeaMED's capabilities against the merits of designing, engineering and
manufacturing instruments internally. SeaMED also faces competition from design
firms and other manufacturers that operate in the medical technology industry.
Most of SeaMED's customers have substantially greater financial and research and
development resources than SeaMED and either operate internal design and
manufacturing facilities or have sufficient resources to develop internal design
and manufacturing capabilities. As a result of the consolidation of smaller
manufacturers into larger manufacturers, some existing or prospective customers
may be eliminated. In the future, SeaMED may also compete against new entrants
to the industry. For example, a medical technology company with design and
manufacturing capabilities (especially one with excess capacity) could decide to
compete with SeaMED for outsource development and manufacturing of medical
instruments. In addition, several large electronic contract manufacturers and
defense department contractors with extensive engineering expertise may from
time to time undertake design and/or manufacture of medical instruments.
Although the Company is not aware of substantial competition from these
noncustomer sources to date, there can be no assurance that these or other
formidable competitors will not aggressively expand into the Company's targeted
market segment in the future. Competition from any of the foregoing sources
could place pressure on SeaMED to accept lower margins on its contracts or lose
existing or potential business, which could result in a material adverse effect
on the Company's business, results of operations and financial condition. See
"Business -- Competition"
UNCERTAINTY OF MARKET ACCEPTANCE OF OUTSOURCING MANUFACTURE OF MEDICAL
INSTRUMENTS
SeaMED believes that the market for outsourcing the manufacture of advanced
medical instruments for medical technology companies is in its early stages.
SeaMED's engineering and manufacturing activities require that customers provide
SeaMED with access to their proprietary technology and relinquish the control
associated with internal engineering and manufacturing. As a result, potential
customers may decide that the risks of outsourcing engineering or manufacturing
are too great or exceed the anticipated benefits of outsourcing. In addition,
medical technology companies that have previously made substantial investments
to establish design and manufacturing capabilities may be reluctant to outsource
those functions. If the medical technology industry generally, or any
significant existing or potential customer, concludes that the disadvantages of
outsourcing manufacturing outweigh the advantages, SeaMED could suffer a
substantial diminution in the size of its target market, which would have a
material adverse effect on its business, results of operations and financial
condition.
COMPLIANCE WITH REGULATORY AGENCY REQUIREMENTS
SeaMED is subject to a variety of regulatory agency requirements in the
United States and foreign countries relating to the instruments that it
manufactures for its customers. The process of obtaining and maintaining
required regulatory approvals and otherwise remaining in regulatory compliance
in the United States and certain other countries is lengthy, expensive and
uncertain.
Applicable law requires that SeaMED comply with the FDA's detailed good
manufacturing practices ("GMP") regulations for the manufacture of medical
products. The FDA monitors compliance with its GMP regulations by subjecting
medical product manufacturers to periodic FDA inspections of their manufacturing
facilities. The FDA has recently revised the GMP regulations. The new
regulations include authority for the FDA to regulate the design phase as well
as the manufacture of medical products and make a number of other significant
changes in the requirements applicable to manufacturers. To ensure compliance
with GMP requirements, SeaMED expends significant time, resources and effort in
the areas of training, production and quality assurance. In addition, the FDA
typically inspects a manufacturer of a PMA device before approving a PMA. The
failure to pass such an inspection could result in delay in approving a PMA.
SeaMED is also subject to other regulatory requirements, and may need to submit
reports to the FDA relating to certain types
9
<PAGE> 10
of adverse events. Failure to comply with GMP regulations or other applicable
legal requirements can lead to warning letters, seizure of violative products,
injunctive actions brought by the U.S. government and potential civil or
criminal liability on the part of the Company and of the officers and employees
who are responsible for the activities that lead to any violation. In addition,
the continued sale of any instruments manufactured by the Company may be halted
or otherwise restricted. Any such actions could have an adverse effect on the
willingness of customers and prospective customers to do business with SeaMED.
In order for the Company's instruments to be exported and for SeaMED and its
customers to be qualified to use the CE mark, the Company maintains
International Organization for Standardization ("ISO") 9001/EN 46001
certification, which subjects SeaMED's operations to periodic surveillance
audits. The ultimate regulatory risks present in manufacturing products for
markets governed by these standards are currently substantially similar to those
posed by GMP regulations. There can be no assurance that the Company's
manufacturing operations will be found to comply with GMP regulations, ISO
standards or other applicable legal requirements or that the Company will not be
required to incur substantial costs to maintain its compliance with existing or
future manufacturing regulations, standards or other requirements. Any such
noncompliance or increased cost of compliance could have a material adverse
effect on the Company's business, results of operations and financial condition.
SeaMED also is subject to numerous federal, state and local laws relating
to such matters as safe working conditions, manufacturing practices,
environmental protection, fire hazard control and disposal of hazardous or
potentially hazardous substances. While SeaMED has not been the subject of any
material proceeding concerning such laws and believes it is currently in
compliance with such laws in all material respects, there can be no assurance
that SeaMED will not be required to incur significant costs to comply with such
laws and regulations now or in the future or that such laws or regulations will
not have a material adverse effect upon the Company's ability to do business.
Changes in existing requirements or adoption of new requirements or policies
could affect adversely the ability of SeaMED to comply with regulatory
requirements. Failure to comply with regulatory requirements could have a
material adverse effect on the Company's business, results of operations or
financial condition. There can be no assurance that the Company will not be
required to incur significant costs to comply with applicable laws and
regulations in the future or that such laws and regulations will not have a
material adverse effect on the Company's business, results of operations or
financial condition. See "Business -- Quality Assurance and Regulatory
Compliance" and "Business -- Governmental Regulation."
PRODUCT RECALLS, PRODUCT LIABILITY AND INSURANCE
Many of the instruments SeaMED designs or manufactures are life-sustaining,
life-supporting or implantable medical products. The tolerance for error in the
design, manufacture or use of these products may be small or nonexistent. If an
instrument designed or manufactured by the Company is found to be defective,
whether due to design or manufacturing defects, to improper use of the product
or to other reasons, the instrument may need to be recalled, possibly at the
Company's expense. Furthermore, the adverse effect of a product recall on the
Company might not be limited to the cost of the recall. For example, a product
recall could cause a general investigation of the Company by applicable
regulatory authorities as well as cause other customers to review and
potentially terminate their relationships with the Company. Recalls, especially
if accompanied by unfavorable publicity or termination of customer contracts,
could result in substantial costs, loss of revenues and a diminution of the
Company's reputation, each of which would have a material adverse effect on the
Company's business, results of operations and financial condition.
The manufacture and sale of the medical instruments manufactured by SeaMED
involve the risk of product liability claims. Although SeaMED generally obtains
indemnification from its customers for instruments it manufactures to the
customers' specifications and in addition maintains product liability insurance,
there can be no assurance that the indemnities will be honored or the coverage
of the Company's insurance policies will be adequate. In addition, SeaMED
generally provides a design defect warranty and indemnifies its customers for
failure of an instrument to conform to design specifications and against defects
in materials and workmanship. SeaMED intends to evaluate its insurance coverage
from time to time in view of developments in its business and products currently
under development. Product liability insurance is
10
<PAGE> 11
expensive and in the future may not be available on acceptable terms, in
sufficient amounts, or at all. A successful claim brought against the Company in
excess of its insurance coverage or any material claim for which insurance
coverage was denied or limited and for which indemnification was not available
could have a material adverse effect on the Company's business, results of
operations and financial condition. See "Business -- Quality Assurance and
Regulatory Compliance."
DEPENDENCE ON KEY PERSONNEL
SeaMED's future success depends to a significant extent on the continued
service of certain of its key managerial, technical and engineering personnel,
particularly its President and Chief Executive Officer, W. Robert Berg, and its
continuing ability to attract, train, assimilate and retain highly qualified
engineering, technical and managerial personnel experienced in commercializing
medical products. Competition for such personnel is intense, the available pool
of qualified candidates is limited and there can be no assurance that SeaMED can
retain its key engineering, technical and managerial personnel or that it can
attract, train, assimilate or retain other highly qualified engineering,
technical and managerial personnel in the future. The loss of Mr. Berg or any of
SeaMED's other key personnel or the inability of SeaMED to hire, train,
assimilate or retain qualified personnel could have a material adverse effect on
the Company's business, results of operations and financial condition. None of
the Company's key personnel has an employment agreement with the Company. The
Company has obtained key-man life insurance policies on the life of W. Robert
Berg in the amount of $2 million. See "Management."
POTENTIAL INABILITY TO SUSTAIN AND MANAGE GROWTH
SeaMED's ability to manage its growth effectively will require it to
continue to implement and improve its operational, financial and management
information systems, to develop its managers' and project engineers' management
skills and to train, motivate and manage its employees. If SeaMED cannot keep
pace with the growth of its customers, it may lose customers and its growth may
be limited. In particular, to accommodate future growth SeaMED may need to
obtain additional space to continue manufacturing at optimum levels. SeaMED
currently obtains additional manufacturing space based on its projected needs,
which are based on, but do not necessarily reflect, its customers' production
forecasts. As a result, the Company may from time to time have insufficient
manufacturing facilities to fulfill on a timely basis unexpected and significant
increases in customer orders. Although an existing manufacturing facility for
PMA products may be able to be expanded without prior regulatory approval,
establishing a new manufacturing facility for PMA products requires prior
regulatory approval, which may cause production delays. The Company could lose
customer business or miss growth opportunities in the future if it were unable
to obtain adequate additional space on a timely basis. Conversely, if one or
more customers were to cancel production orders, the Company may incur
substantial lease obligations, resulting in excess production capacity, which
could have a material adverse effect on the Company's business, results of
operations and financial condition.
SeaMED's business, both operationally and administratively, depends on
SeaMED's ability to store, retrieve, process, manage and share significant
amounts of information. In addition, SeaMED depends on its computer system to
integrate its manufacturing processes with its quality assurance procedures
(including, for example, maintaining distribution records and allowing for the
tracing of certain product lots) to comply with GMP requirements and ISO 9001
standards. Although SeaMED believes that its existing computer system will
adequately serve its near-term needs, it may need to upgrade its computer system
if significant growth continues. Any difficulties or delays in upgrading the
computer system, or in remaining in compliance with applicable GMP requirements
and ISO 9001 standards, could adversely affect the manufacture and delivery of
customer instruments, and the Company's management, reporting and internal
control systems.
The Company's failure to manage growth effectively could have a material
adverse effect on its business, results of operations and financial condition.
11
<PAGE> 12
LIMITED SUPPLIERS AND SHORTAGES OF COMPONENT PARTS
SeaMED relies on third-party suppliers for each of the component parts used
in manufacturing its customers' instruments. Although component parts are
generally available from multiple suppliers, certain component parts may require
long lead times, and SeaMED may have to delay the manufacture of customer
instruments from time to time due to the unavailability of certain component
parts. In addition, even if component parts are available from an alternative
supplier, SeaMED could experience additional delays in obtaining component parts
if the supplier has not met SeaMED's vendor qualifications. Component shortages
for a particular instrument may adversely affect the Company's ability to
satisfy customer orders for that instrument. At various times, there have been
shortages of component parts, especially electronics components. After
consultation with affected customers, the Company has typically extended
production schedules pending receipt of the delayed components. Such shortages
and extensions of production schedules may delay the recognition of revenue by
the Company and may in some cases constitute a breach of a customer contract,
which may have a material adverse effect on SeaMED's business, results of
operations and financial condition. If existing shortages of component parts
continue or if additional shortages should occur, the Company may be forced to
pay higher prices for affected components or delay manufacturing and shipping
particular instruments, either of which could adversely affect customer demand
for such instruments and the Company's business, results of operations and
financial condition.
CUSTOMER CONFLICTS
The medical technology industry reflects vigorous competition among its
participants, sometimes leading to substantial animosity between competitors.
SeaMED's growth may be adversely affected if its customers require SeaMED to
enter into noncompetition agreements that prevent SeaMED from manufacturing
instruments for its customers' competitors. For example, if SeaMED enters into a
noncompetition agreement, SeaMED may be adversely affected if its customer's
product is not successful and SeaMED must forgo an opportunity to manufacture a
successful instrument for such customer's competitor. Any conflicts among its
customers could prevent or deter SeaMED from obtaining contracts to manufacture
successful instruments, which could result in a material adverse effect on its
business, results of operations and financial condition.
FUTURE CAPITAL REQUIREMENTS
SeaMED believes that the net proceeds of this offering, together with
existing capital resources and amounts available under the Company's existing
bank line of credit, will satisfy the Company's anticipated capital needs for
the next 12 to 24 months (depending primarily on SeaMED's growth rate and its
results of operations). Thereafter, SeaMED may be required to raise additional
capital or increase its borrowing capacity, or both. There can be no assurance
that alternative sources of equity or debt will be available in the future or,
if available, will be on terms acceptable to SeaMED. Any additional equity
financing would result in additional dilution to the Company's shareholders,
including shareholders who purchase Common Stock in this offering. See
"Management's Discussion and Analysis of Financial Condition and Results of
Operations."
CONTROL BY MANAGEMENT
Following this offering, the current executive officers and directors of
SeaMED and their affiliates will beneficially own or have voting control over
approximately 43.7% of the outstanding Common Stock (approximately 41.6% if the
Underwriters' over-allotment option is exercised in full). Accordingly, these
individuals will have the ability to influence the election of the Company's
directors and to effectively control most corporate actions. This concentration
of ownership, together with other provisions in the Company's charter and
applicable corporate law, may also have the effect of delaying, deterring or
preventing a change in control of the Company. See "Principal and Selling
Shareholders" and "Description of Capital Stock."
ANTITAKEOVER EFFECT OF CERTAIN CHARTER PROVISIONS AND LAWS
Pursuant to SeaMED's Articles of Incorporation, the Board of Directors is
authorized to issue 5,000,000 shares of Preferred Stock, no par value (the
"Undesignated Preferred Stock"), in one or more classes or
12
<PAGE> 13
series, or both, and, without further approval of the shareholders, to fix
dividend rights and terms, conversion rights, voting rights, redemption rights
and terms, liquidation preferences and any other rights, preferences, privileges
and restrictions applicable to each class or series of Undesignated Preferred
Stock. The issuance of Undesignated Preferred Stock could, among other things,
adversely affect the voting power of the holders of Common Stock and, under
certain circumstances, make it more difficult for a third party to gain control
of the Company, discourage bids for Common Stock at a premium or otherwise
adversely affect the market price of the Common Stock. The Company's Bylaws
contain certain procedural requirements that could have the effect of delaying
the ability of some shareholders to bring matters before a meeting of the
shareholders or to nominate directors. The Washington Business Corporation Act
(the "Washington Business Act") contains certain provisions that may have the
effect of delaying or discouraging a hostile takeover of the Company. See
"Description of Capital Stock -- Certain Provisions of Articles of Incorporation
and Bylaws" and " -- Provisions Affecting Acquisitions and Business
Combinations."
ABSENCE OF PRIOR MARKET; POTENTIAL VOLATILITY OF COMMON STOCK PRICE
Prior to this offering, there has been no public market for the Common
Stock, and there can be no assurance that an active trading market will develop
or be sustained. The initial public offering price for the Common Stock was
determined by negotiations between the Company and the representatives of the
Underwriters and may not be indicative of the market price of the Common Stock
after this offering. See "Underwriting." The market price of the Common Stock
may be volatile and may fluctuate based on a number of factors, including
significant announcements by the Company and its competitors, quarterly
fluctuations in the Company's operating results and general economic conditions
and conditions in the medical technology industry. In addition, in recent years
the stock market has experienced extreme price and volume fluctuations, which
have had a substantial effect on the market prices for many medical-technology
companies and are often unrelated to the operating performance of such
companies.
SHARES ELIGIBLE FOR FUTURE SALE
Sales of substantial amounts of Common Stock in the public market after
this offering could adversely affect the market price of the Common Stock. Of
the 5,136,906 shares outstanding following this offering, the 1,850,000 shares
sold hereby will be freely tradable in the public market and the remaining
3,286,906 shares will be "restricted securities" within the meaning of Rule 144
promulgated under the Securities Act of 1933, as amended (the "Securities Act").
Approximately 56,051 restricted securities will be eligible for sale immediately
following this offering in reliance on Rule 144(k) under the Securities Act.
Approximately 7,558 restricted securities will be eligible for sale 90 days
following this offering in reliance on other provisions of Rule 144 and on Rule
701. Beginning 180 days after the closing of this offering, following the
expiration of certain lockup agreements among the Underwriters, the Selling
Shareholders, the Company's officers and directors and certain other
shareholders of the Company, 2,900,964 additional currently outstanding shares
of Common Stock will be eligible for sale in the public market, subject to the
limitations of Rule 144 and Rule 701. If the Securities and Exchange Commission
(the "Commission") adopts proposed amendments to Rule 144 to substantially
reduce required holding periods for restricted securities, another 322,333
currently outstanding shares of Common Stock will be eligible for sale in the
public market as described in the preceding sentence. In addition, certain
shareholders, representing approximately 2,727,104 shares of Common Stock, have
the right, subject to certain conditions, to include their shares in future
registration statements relating to SeaMED's securities and to cause SeaMED to
register certain shares of Common Stock owned by them. An additional 39,066
shares of Common Stock issuable upon exercise of an outstanding warrant and
586,617 shares of Common Stock reserved for issuance pursuant to the Company's
stock option plans (the "Option Shares"), may become eligible for resale in the
public market at various times after the expiration of the 180-day lockup
period. The holders of 154,700 Option Shares which have vested and are not
subject to lockup agreements could exercise their options and sell these shares
in compliance with Rule 701 beginning 90 days after the effective date of this
offering. The Company intends to register the Option Shares for resale in the
public market following expiration of the lockup period. See "Shares Eligible
for Future Sale."
13
<PAGE> 14
NO SPECIFIC USE FOR SIGNIFICANT PORTION OF NET PROCEEDS
SeaMED has not designated any specific use for the net proceeds of this
offering remaining after payment of outstanding bank debt and the dividend on
certain shares of its preferred stock. SeaMED intends to use the remaining net
proceeds to fund working capital needs and for general corporate purposes,
including leasehold improvements and purchases of equipment, and may, if the
opportunity arises, use an unspecified portion of the net proceeds to acquire
other manufacturing or engineering businesses or assets that complement SeaMED's
existing business. Accordingly, management will have significant flexibility in
applying the net proceeds of this offering. See "Use of Proceeds."
DILUTION
Purchasers of the Common Stock offered hereby will incur immediate and
substantial dilution in the net tangible book value per share of the Common
Stock from the initial public offering price in the amount of $7.09 per share.
See "Dilution."
ABSENCE OF DIVIDENDS
The Company has never paid dividends on the Common Stock and does not
anticipate paying any such dividends in the foreseeable future. In addition, the
Company's current revolving credit facility prohibits the payment of dividends,
but such restriction has been waived for the payment of cumulative dividends on
Class A and Class D Preferred Stock upon the closing of this offering. See
"Dividend Policy."
14
<PAGE> 15
USE OF PROCEEDS
The net proceeds to the Company from the sale of 1,529,720 shares of Common
Stock offered hereby are estimated to be approximately $14.8 million
(approximately $17.6 million if the Underwriters' over-allotment option is
exercised in full), after deducting estimated underwriting discounts and
offering expenses.
The Company intends to use a portion of such net proceeds to repay bank
debt consisting of a bank line of credit and three notes payable, the aggregate
outstanding balance of which is expected to be between $3.5 million and $5.0
million, and approximately $1.8 million of the net proceeds to pay cumulative
dividends on Class A and Class D Preferred Stock. The three notes payable have
interest rates of 8.5%, 8.75% and 8.75% and maturity dates of August 5, 1998,
November 5, 1999 and July 5, 2000, respectively. See "Management's Discussion
and Analysis of Financial Condition and Results of Operations -- Liquidity and
Capital Resources." The Company intends to use the remaining net proceeds
(ranging from $8.0 million to $9.5 million ($10.8 million to $12.3 million if
the Underwriters' over-allotment is exercised in full)) to fund working capital
needs and for general corporate purposes, including leasehold improvements and
purchases of equipment. The Company, if the opportunity arises, may use an
unspecified portion of the net proceeds to acquire other manufacturing or
engineering businesses or assets that complement the Company's existing
business. The Company currently is not engaged in any discussions regarding such
acquisitions and has no plans, arrangements, understandings or agreements
regarding any specific acquisition.
Pending the uses set forth above, the net proceeds will be invested in
short-term, investment-grade, interest-bearing securities. The Company will not
receive any proceeds from the sale of Common Stock by the Selling Shareholders.
See "Principal and Selling Shareholders."
DIVIDEND POLICY
The Company has never paid dividends on the Common Stock, and currently
intends to retain all earnings for use in the expansion of its business, and
does not anticipate paying any dividends on the Common Stock in the foreseeable
future. In addition, the Company's current revolving credit facility prohibits
the payment of dividends, but such restriction has been waived for the payment
of cumulative dividends on Class A and Class D Preferred Stock upon the closing
of this offering.
15
<PAGE> 16
DILUTION
The Company's pro forma net tangible book value as of September 30, 1996
was approximately $5.3 million, or $1.46 per share. Pro forma net tangible book
value per share represents the Company's total assets less intangible assets and
total liabilities divided by the number of shares outstanding, adjusted on a pro
forma basis for the (i) conversion into Common Stock of all outstanding shares
of Preferred Stock and (ii) pro forma accrual of $1.7 million of cumulative
dividends on Class A and D Preferred Stock as of September 30, 1996. Without
taking into account any changes in such net tangible book value per share after
September 30, 1996, other than to give effect to the sale of the shares of
Common Stock offered by the Company hereby and the receipt of the estimated net
proceeds of such sale, the pro forma net tangible book value per share as of
September 30, 1996 would have been approximately $20.1 million, or $3.91 per
share. This represents an immediate increase in net tangible book value per
share of $2.45 to existing shareholders and an immediate dilution of $7.09 per
share to new investors. The following table sets forth this per share dilution:
<TABLE>
<S> <C> <C>
Initial public offering price per share..................................... $11.00
Pro forma net tangible book value per share as of September 30, 1996...... $1.46
Increase per share attributable to new investors.......................... 2.45
------
Pro forma net tangible book value per share after this offering............. 3.91
------
Dilution per share to new investors......................................... $ 7.09
======
</TABLE>
The following table summarizes, on a pro forma basis as of September 30,
1996, the differences between existing shareholders and investors in this
offering with respect to the number of shares of Common Stock purchased from the
Company, the total consideration paid and the average price per share paid.
<TABLE>
<CAPTION>
SHARES
PURCHASED(1)(2) TOTAL CONSIDERATION
--------------------- ----------------------- AVERAGE PRICE
NUMBER PERCENT AMOUNT PERCENT PER SHARE
--------- ------- ----------- ------- -------------
<S> <C> <C> <C> <C> <C>
Existing shareholders............... 3,607,186 70.2% $ 5,533,472 24.7% $ 1.53
New investors....................... 1,529,720 29.8 16,826,920 75.3 11.00
--------- ----- ---------- -----
Total..................... 5,136,906 100.0% $22,360,392 100.0%
========= ===== ========== =====
</TABLE>
- ---------------
(1) Excludes 529,265 shares of Common Stock issuable upon exercise of stock
options and a warrant outstanding at such date, which had a weighted average
exercise price of $2.56 per share. Also excludes 96,418 shares reserved for
issuance pursuant to future option grants under the Company's stock option
plans. See "Management -- Stock Plans" and "Description of Capital Stock."
To the extent these options and this warrant are exercised, there will be
further dilution to new investors.
(2) Sales by the Selling Shareholders in this offering will reduce the number of
shares held by existing shareholders as of September 30, 1996 to
approximately 3,286,906 shares, or 64.0% (60.7% if the Underwriters'
over-allotment option is exercised in full) of the total number of shares of
Common Stock outstanding after this offering, and will increase the number
of shares to be purchased by new investors to 1,850,000 shares, or 36.0%
(approximately 2,127,500 shares, or 39.3% if the Underwriters'
over-allotment option is exercised in full) of the total number of shares of
Common Stock outstanding after this offering. See "Principal and Selling
Shareholders."
16
<PAGE> 17
CAPITALIZATION
The following table sets forth (i) the actual capitalization of the Company
as of September 30, 1996, (ii) the pro forma capitalization after giving effect
to the conversion of all outstanding shares of Preferred Stock into 2,934,029
shares of Common Stock upon the closing of this offering and the pro forma
accrual of $1.7 million of cumulative dividends on Class A and D Preferred Stock
as of September 30, 1996, and (iii) the adjusted capitalization after giving
effect to the sale by the Company of the 1,529,720 shares of Common Stock
offered by it hereby, and the application of the estimated net proceeds thereof.
<TABLE>
<CAPTION>
SEPTEMBER 30, 1996
------------------------------------
ACTUAL PRO FORMA AS ADJUSTED
------ --------- -----------
<S> <C> <C> <C>
(in thousands)
Notes payable to bank....................................... $2,246 $ 2,246 $ --
======= ======= =======
Current portion of long-term debt........................... $ 583 $ 583 $ 135
======= ======= =======
Long-term debt, net of current portion...................... $1,535 $ 1,535 $ 616
Convertible redeemable preferred stock...................... 5,280 -- --
Shareholders' equity:
Preferred stock, no par value, 14,050,000 shares
authorized; 9,050,000 designated convertible redeemable
shares................................................. -- -- --
Common stock, no par value, 10,000,000 shares authorized;
673,157 shares issued and outstanding actual; 3,607,186
shares issued and outstanding pro forma; 5,136,906
shares issued and outstanding as adjusted(1)........... 889 5,345 20,144
Note receivable from officer.............................. (75) (75) (75)
Retained earnings......................................... 906 -- --
------- ------- -------
Total shareholders' equity........................... 1,720 5,270 20,069
------- ------- -------
Total capitalization.............................. $8,535 $ 6,805 $20,685
======= ======= =======
</TABLE>
- ---------------
(1) Excludes 529,265 shares issuable upon exercise of stock options and a
warrant outstanding at such date, which had a weighted average exercise
price of $2.56 per share. Also excludes 96,418 shares reserved for issuance
pursuant to future option grants under the Company's stock option plans. See
"Management -- Stock Plans" and "Description of Capital Stock."
17
<PAGE> 18
SELECTED FINANCIAL DATA
(in thousands, except per share amounts)
The following selected financial data as of June 30, 1995 and 1996, and for
each of the periods ended June 30, 1994, 1995 and 1996, are derived from the
financial statements of the Company, which have been audited by Ernst & Young
LLP, independent auditors, and are included elsewhere in this Prospectus. The
selected financial data as of June 30, 1992, 1993 and 1994, and for each of the
periods ended June 30, 1992 and 1993, are derived from audited financial
statements not included herein. The selected financial data as of September 30,
1996 and for the quarters ended September 30, 1995 and 1996 are derived from
unaudited financial statements of the Company, which in the opinion of
management include all adjustments, consisting only of normal recurring
adjustments, necessary for a fair presentation of the financial information set
forth therein. The results for the quarter ended September 30, 1996 are not
necessarily indicative of the results that may be expected for the entire year.
The Company's fiscal year consists of the 52/53-week period that ends on the
Thursday nearest to June 30. For convenience of presentation, all fiscal periods
in this Prospectus are shown as ending on a calendar month-end. The data should
be read in conjunction with the Financial Statements and Notes thereto and
"Management's Discussion and Analysis of Financial Condition and Results of
Operations" included elsewhere in this Prospectus.
<TABLE>
<CAPTION>
QUARTER
YEAR ENDED JUNE 30, ENDED SEPTEMBER 30,
----------------------------------------------------- ------------------
1992 1993 1994 1995 1996 1995 1996
------ ------ ------- ------- ------- ------ -------
<S> <C> <C> <C> <C> <C> <C> <C>
STATEMENT OF INCOME DATA:
Revenues......................... $8,663 $9,582 $14,720 $17,661 $26,130 $5,000 $10,076
Cost of sales.................... 6,426 7,444 11,965 14,590 21,093 4,207 8,391
------ ------ ------- ------- ------- ------ -------
2,237 2,138 2,755 3,071 5,037 793 1,685
Marketing, general and
administrative expenses........ 1,430 1,239 1,818 1,931 2,937 491 847
------ ------ ------- ------- ------- ------ -------
Operating income................. 807 899 937 1,140 2,100 302 838
Other expense, net............... 106 114 138 185 192 49 89
------ ------ ------- ------- ------- ------ -------
Income before income taxes....... 701 785 799 955 1,908 253 749
Income tax benefit
(provision)(1)................. (19) 245 208 (180) (668) (86) (262)
------ ------ ------- ------- ------- ------ -------
Net income....................... $ 682 $1,030 $ 1,007 $ 775 $ 1,240 $ 167 $ 487
====== ====== ======= ======= ======= ====== =======
Net income per share data(2):
Primary........................ $ 0.26 $ 0.42 $ 0.39 $ 0.25 $ 0.42 $ 0.04 $ 0.17
====== ====== ======= ======= ======= ====== =======
Fully diluted.................. $ 0.21 $ 0.31 $ 0.30 $ 0.21 $ 0.32 $ 0.04 $ 0.12
====== ====== ======= ======= ======= ====== =======
</TABLE>
<TABLE>
<CAPTION>
JUNE 30, PRO FORMA
--------------------------------------------- SEPTEMBER 30, SEPTEMBER 30,
1992 1993 1994 1995 1996 1996 1996(3)
------- ------- ------ ------ ------- ------------- -------------
<S> <C> <C> <C> <C> <C> <C> <C>
BALANCE SHEET DATA:
Working capital..................... $ 1,770 $ 2,686 $3,307 $4,497 $ 4,997 $ 5,477 $ 3,747
Total assets........................ 3,616 4,903 7,571 9,900 16,064 16,538 16,538
Notes payable to bank............... -- -- 990 555 1,817 2,246 2,246
Long-term debt,
including current portion......... 1,185 1,370 1,653 1,517 1,748 2,119 2,119
Convertible redeemable preferred
stock............................. 3,815 3,815 3,815 5,280 5,280 5,280 --
Total shareholders' equity
(deficit)......................... (2,747) (1,713) (672) (38) 1,231 1,720 5,270
</TABLE>
- ---------------
(1) For the fiscal years ended June 30, 1992, 1993 and 1994, reflects the
benefit of utilization of net operating loss carryforwards, tax credit
carryforwards and related changes in the deferred tax asset valuation
allowance.
(2) See Note 1 of Notes to Financial Statements for an explanation of the number
of shares used in computing net income per share.
(3) The pro forma balance sheet data as of September 30, 1996 reflect the pro
forma conversion into shares of Common Stock of all outstanding shares of
Preferred Stock and the pro forma accrual of $1.7 million of cumulative
dividends on Class A and D Preferred Stock.
18
<PAGE> 19
MANAGEMENT'S DISCUSSION AND ANALYSIS
OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The following discussion and analysis should be read in conjunction with
the Company's Financial Statements and Notes thereto and other financial
information included elsewhere in this Prospectus. This Prospectus contains, in
addition to historical information, forward-looking statements that involve
risks and uncertainties. The Company's actual results could differ materially
from the results discussed in the forward-looking statements. Factors that could
cause or contribute to such differences include those discussed below, as well
as those discussed elsewhere in this Prospectus. See "Risk Factors."
OVERVIEW
SeaMED is a manufacturer of advanced medical instruments for medical
technology companies. SeaMED was incorporated in 1976, and since 1988 has
focused its business primarily on manufacturing medical instruments for medical
technology companies. To assist its customers in developing and commercializing
their products for manufacture by SeaMED, the Company provides a wide range of
engineering services and regulatory expertise. SeaMED's revenues have grown from
$8.7 million in fiscal year 1992 to $26.1 million in fiscal year 1996, a
compound annual growth rate of 32%, and its operating income has grown from
$807,000 in fiscal year 1992 to $2.1 million in fiscal year 1996, a compound
annual growth rate of 27%.
SeaMED's manufacturing contracts with its customers are usually exclusive
contracts for a fixed period of time, generally ranging from three to five
years. SeaMED negotiates each manufacturing contract independently, and each
varies as to profitability. SeaMED negotiates the price of each manufactured
instrument on a cost and margin formula. SeaMED's contracts with its customers
generally permit annual manufacturing cost audits and price renegotiations.
During the contract term, customers have broad discretion to control the volume
and timing of instrument deliveries. Consequently, SeaMED's revenues with
respect to each instrument may vary substantially from period to period, and an
instrument that generates revenues in one quarter may not necessarily generate
revenues in each quarter of a fiscal year. In addition, for a variety of reasons
such as a customer's inventory levels, sales mix and timing of product launches,
SeaMED's revenues for an instrument do not necessarily correspond to the
customer's sales.
Manufacturing revenue growth depends primarily on two factors: increased
demand for instruments manufactured by SeaMED and SeaMED's ability to attract
additional manufacturing contracts from emerging and established medical
technology companies. SeaMED has no ability to increase demand for the
instruments it manufactures because SeaMED's customers control all product
marketing and sales. SeaMED markets its manufacturing capabilities and usually
procures additional manufacturing contracts as a result of its engineering
projects, but the volume and timing of future manufacturing revenues that relate
to any specific engineering project are highly variable, and certain engineering
projects may not lead to future manufacturing revenues. The manufacturing gross
margin percentage from year to year depends primarily on the product mix, as
gross margins vary by instrument and as a result of negotiated volume discounts.
Management may negotiate volume discounts if the larger volume results in
smaller per unit overhead allocation, thereby improving operating margin. For
manufacturing revenues from instruments not yet approved for commercial use
(known as "preproduction revenues"), the gross margin percentage is generally
lower because a smaller number of units limits opportunities to achieve
economies of scale, and the instrument and its manufacturing process are being
refined.
SeaMED provides its customers with engineering services at any stage of an
instrument's development, as part of its strategy to obtain exclusive
manufacturing rights for an instrument. SeaMED generally provides engineering
services under a project plan that identifies the engineering tasks,
deliverables and schedule. SeaMED negotiates each engineering project plan
independently, and, as a business strategy, generally prices engineering
contracts to cover direct project expenses (i.e., nonrecurring engineering
expenses) plus a share of marketing, general and administrative expenses.
SeaMED's objective in providing engineering services is to obtain, for a
specific time period (usually three to five years), exclusive manufacturing
rights to the instrument resulting from the engineering project. The customer
can typically cancel the engineering project at any time upon short notice.
19
<PAGE> 20
Engineering revenues are derived primarily from professional services
provided by SeaMED's engineers. The balance of engineering revenues is sales of
materials to customers at cost. Engineering revenue growth depends primarily on
three factors: (i) the number and scope of existing engineering projects, (ii)
whether existing projects are in time-intensive phases, and (iii) whether new
engineering projects of sufficient scope replace engineering projects that are
completed or otherwise terminated. Engineering gross margins are low due to
SeaMED's strategy of pricing engineering services as part of an exclusive
manufacturing contract for the resulting instrument. Since demand for
engineering services varies widely, SeaMED may experience from time to time
excess engineering capacity. Engineering margins may fluctuate depending on the
rates that customers pay under engineering project plans and the utilization
rates of engineers.
SeaMED from time to time selectively designs and manufactures nonmedical
commercial products that benefit from SeaMED's engineering and manufacturing
capabilities. SeaMED intends to maintain as its primary focus the design and
manufacturing of advanced medical instruments for medical technology companies.
SeaMED has historically designed, developed and manufactured certain
proprietary instruments. SeaMED expects that fiscal year 1997 will be the last
year in which it derives revenues from such instruments. SeaMED thereafter will
derive its revenues exclusively by manufacturing instruments for its customers.
SeaMED's revenues from its proprietary instruments were $1.2 million, $923,000,
$1.4 million and $451,000 in fiscal years 1994, 1995 and 1996 and the first
quarter of fiscal year 1997, respectively.
Marketing, general and administrative expenses include the costs of
SeaMED's marketing, finance, and management information systems departments and
other administrative costs. In addition, marketing, general and administrative
expenses include the cost of a Company-wide bonus tied to operating performance.
RESULTS OF OPERATIONS
COMPARISON OF QUARTERS ENDED SEPTEMBER 30, 1995 AND 1996
The following table sets forth statement of income data as a percentage of
revenues for the quarters indicated.
<TABLE>
<CAPTION>
QUARTER ENDED
SEPTEMBER 30,
-----------------
1995 1996
----- -----
<S> <C> <C>
Revenues........................................................... 100.0% 100.0%
Cost of sales...................................................... 84.1 83.3
----- -----
Gross margin....................................................... 15.9 16.7
Marketing, general and administrative expenses..................... 9.9 8.4
----- -----
Operating income................................................... 6.0 8.3
Other expense, net................................................. 1.0 0.9
----- -----
Income before income taxes......................................... 5.0 7.4
Income tax provision............................................... 1.7 2.6
----- -----
Net income......................................................... 3.3% 4.8%
===== =====
</TABLE>
Revenues
The following table sets forth revenues with the corresponding percentage
of total revenues and the quarter to quarter percentage increase for the
quarters indicated.
<TABLE>
<CAPTION>
QUARTER ENDED SEPTEMBER 30,
------------------------------------------------------------
1995 1996
--------------------- ---------------------
% OF % OF
TOTAL TOTAL %
REVENUES REVENUES REVENUES REVENUES INCREASE
-------- -------- -------- -------- --------
(dollars in thousands)
<S> <C> <C> <C> <C> <C>
Manufacturing.............................. $3,475 69.5% $ 6,724 66.7% 93.5%
Engineering................................ 1,525 30.5 3,352 33.3 119.8%
------ ----- ------- -----
Total revenues........................... $5,000 100.0% $ 10,076 100.0% 101.5%
====== ===== ======= =====
</TABLE>
20
<PAGE> 21
Manufacturing revenues increased by approximately $3.2 million from the
first quarter of fiscal year 1996 to the first quarter of fiscal year 1997, due
primarily to a new nonmedical product manufactured for Coinstar under a
nonexclusive contract adding approximately $2.3 million in revenues, new
instruments adding approximately $667,000 in revenues and increased revenues
from existing instruments adding approximately $1.5 million. SeaMED began sales
to Coinstar in the fourth quarter of fiscal year 1996, and sales to Coinstar in
the first quarter of fiscal year 1997 represented approximately 25.0% of total
revenues and approximately 33.5% of manufacturing revenues. See "Risk
Factors -- Dependence on Small Number of Customers" and "Business -- Customers
and Products." Increases in manufacturing revenues were offset by decreased
volume of certain existing instruments and the phase-out of other instruments.
Significant manufacturing revenues were generated by 11 instruments in the first
quarter of fiscal year 1996 and 12 instruments and one nonmedical product in the
first quarter of fiscal year 1997.
Engineering revenues increased by approximately $1.8 million from the first
quarter of fiscal year 1996 to the first quarter of fiscal year 1997, due
primarily to new projects adding approximately $1.5 million in revenues, and
increased time and hourly rates being billed on existing projects adding
approximately $763,000 in revenues. Increases in engineering revenues were
offset by the transition of certain projects from engineering to manufacturing
and other projects being delayed or cancelled.
SeaMED intends to maintain as its primary focus the design and
manufacturing of advanced medical instruments for medical technology companies.
Management expects the percentage of the Company's revenues derived from
nonmedical products to decline in subsequent quarters unless SeaMED undertakes
to manufacture another high-volume or high-margin nonmedical product.
Gross Margin
The following table sets forth gross margin, both in dollar amounts and as
a percentage of the corresponding revenue figure for the quarters indicated.
<TABLE>
<CAPTION>
QUARTER ENDED SEPTEMBER 30,
---------------------------------------------------
1995 1996
----------------------- -----------------------
GROSS GROSS GROSS GROSS
MARGIN($) MARGIN(%) MARGIN($) MARGIN(%)
--------- --------- --------- ---------
(dollars in thousands)
<S> <C> <C> <C> <C>
Manufacturing........................... $ 746 21.5% $ 1,285 19.1%
Engineering............................. 47 3.1% 400 11.9%
---- ------
Total gross margin................. $ 793 15.9% $ 1,685 16.7%
==== ======
</TABLE>
Manufacturing gross margin decreased from 21.5% of manufacturing revenues
in the first quarter of fiscal year 1996 to 19.1% in the first quarter of fiscal
year 1997, due primarily to a negative gross margin (loss) on a medical
instrument that will be phased out of full production in the second quarter of
fiscal year 1997 and a negative gross margin on an instrument in preproduction.
The decrease from the fiscal year 1996 manufacturing gross margin percentage of
23.6% to a manufacturing gross margin percentage of 19.1% in the first quarter
of fiscal year 1997 was primarily attributable to the same negative gross
margins. Management expects the fiscal year 1997 manufacturing gross margin
percentage to be lower than the fiscal year 1996 manufacturing gross margin
percentage of 23.6%. Engineering gross margin increased from 3.1% of engineering
revenues in the first quarter of fiscal year 1996 to 11.9% in the first quarter
of fiscal year 1997. This increase reflects a trend of increasing engineering
gross margin percentages, due primarily to (i) spreading certain fixed
engineering costs over a higher revenue base, (ii) better utilization of
engineers, and (iii) increased hourly rates for engineering services. Management
expects the fiscal year 1997 engineering gross margin percentage to be near 10%.
Marketing, General and Administrative Expenses
Marketing, general and administrative expenses increased from $491,000 in
the first quarter of fiscal year 1996 to $847,000 in the first quarter of fiscal
year 1997, but as a percentage of revenues decreased from 9.9% to 8.4% for the
respective quarters (9.1% and 6.2%, respectively, before Company-wide bonus
accruals). The
21
<PAGE> 22
decrease in marketing, general and administrative expenses as a percentage of
revenues is due to increased revenues without a proportionate increased
commitment of marketing, general and administrative resources.
Operating Income
Operating income increased 177.5% from $302,000 (6.0% of revenues) in the
first quarter of fiscal year 1996 to $838,000 (8.3% of revenues) in the first
quarter of fiscal year 1997, due primarily to increased revenues and a decrease
in marketing, general and administrative expenses as a percentage of revenues.
COMPARISON OF YEARS ENDED JUNE 30, 1994, 1995 AND 1996
The following table sets forth statement of income data as a percentage of
revenues for the fiscal years indicated.
<TABLE>
<CAPTION>
YEAR ENDED JUNE 30,
-------------------------
1994 1995 1996
----- ----- -----
<S> <C> <C> <C>
Revenues.................................................... 100.0% 100.0% 100.0%
Cost of sales............................................... 81.3 82.6 80.7
----- ----- -----
Gross margin................................................ 18.7 17.4 19.3
Marketing, general and administrative expenses.............. 12.4 10.9 11.3
----- ----- -----
Operating income............................................ 6.3 6.5 8.0
Other expense, net.......................................... 0.9 1.1 0.7
----- ----- -----
Income before income taxes.................................. 5.4 5.4 7.3
Income tax benefit (provision).............................. 1.4 (1.0) (2.6)
----- ----- -----
Net income.................................................. 6.8% 4.4% 4.7%
===== ===== =====
</TABLE>
Revenues
The following table sets forth revenues with the corresponding percentage
of total revenues and the year-to-year percentage increase for the fiscal years
indicated.
<TABLE>
<CAPTION>
YEAR ENDED JUNE 30,
-------------------------------------------------------------------------------------
1994 1995 1996
------------------- ------------------- -------------------
% OF % OF % OF
TOTAL TOTAL % TOTAL %
REVENUES REVENUES REVENUES REVENUES INCREASE REVENUES REVENUES INCREASE
-------- -------- -------- -------- -------- -------- -------- --------
(dollars in thousands)
<S> <C> <C> <C> <C> <C> <C> <C> <C>
Manufacturing......................... $10,029 68.1% $11,941 67.6% 19.1% $17,725 67.8% 48.4%
Engineering........................... 4,691 31.9 5,721 32.4 22.0% 8,405 32.2 46.9%
-------- -------- -------- -------- -------- --------
Total revenues...................... $14,720 100.0% $17,661 100.0% 20.0% $26,130 100.0% 48.0%
======== ======== ======== ======== ======== ========
</TABLE>
Manufacturing revenues increased by approximately $5.8 million from fiscal
year 1995 to fiscal year 1996, due primarily to new instruments adding
approximately $653,000 in revenues, nonmedical products adding approximately
$1.7 million in revenues and increased revenues from existing instruments adding
approximately $5.2 million. Increases in manufacturing revenues were offset by
decreased volume of certain existing instruments and the phase-out of other
instruments. Although 18 and 23 instruments contributed to manufacturing
revenues in fiscal years 1995 and 1996, respectively, significant manufacturing
revenues were generated by 12 instruments in fiscal year 1995 and 13 instruments
and one nonmedical product in fiscal year 1996. Engineering revenues increased
by approximately $2.7 million from fiscal year 1995 to fiscal year 1996, due
primarily to new projects adding approximately $2.0 million in revenues, and
increased time and hourly rates being billed on existing projects adding
approximately $3.0 million in revenues. Increases in engineering revenues were
offset by the transition of certain projects from engineering to manufacturing
and other projects being delayed or cancelled.
Manufacturing revenues increased by approximately $1.9 million from fiscal
year 1994 to fiscal year 1995, due primarily to new instruments adding
approximately $1.7 million in revenues and increased revenues from existing
instruments adding approximately $2.8 million. Increases in manufacturing
revenues were offset by decreased volume of certain existing instruments.
Although 14 instruments contributed to manufacturing
22
<PAGE> 23
revenues in fiscal year 1994, significant manufacturing revenues were generated
by nine instruments in fiscal year 1994. Engineering revenues increased by
approximately $1.0 million from fiscal year 1994 to fiscal year 1995, due
primarily to new projects adding approximately $894,000 in revenues, and
increased time and hourly rates being billed on existing projects adding
approximately $2.3 million in revenues. Increases in engineering revenues were
offset by the transition of certain projects from engineering to manufacturing
and other projects being delayed or cancelled.
Price adjustments under existing manufacturing contracts have not been
significant. Increases in revenues have not been significantly influenced by
inflation.
Gross Margin
The following table sets forth gross margin, both in dollar amounts and as
a percentage of the corresponding revenue figure for the fiscal years indicated.
<TABLE>
<CAPTION>
YEAR ENDED JUNE 30,
---------------------------------------------------------------------
1994 1995 1996
--------------------- --------------------- ---------------------
GROSS GROSS GROSS GROSS GROSS GROSS
MARGIN($) MARGIN(%) MARGIN($) MARGIN(%) MARGIN($) MARGIN(%)
--------- --------- --------- --------- --------- ---------
(dollars in thousands)
<S> <C> <C> <C> <C> <C> <C>
Manufacturing..................... $ 2,491 24.8% $ 2,611 21.9% $ 4,184 23.6%
Engineering....................... 264 5.6% 460 8.0% 854 10.2%
------ ------ ------
Total gross margin........... $ 2,755 18.7% $ 3,071 17.4% $ 5,038 19.3%
====== ====== ======
</TABLE>
Manufacturing gross margin increased from 21.9% of manufacturing revenues
in fiscal year 1995 to 23.6% in fiscal year 1996, due primarily to changes in
the product mix to higher gross margin products, including a decrease in the
percentage of manufacturing revenues derived from products in preproduction.
Engineering gross margin as a percentage of engineering revenues has increased
from 8.0% in fiscal year 1995 to 10.2% in fiscal year 1996. This trend was due
primarily to (i) spreading certain fixed engineering costs over a higher revenue
base, (ii) better utilization of engineers, and (iii) increased hourly rates for
engineering services.
Manufacturing gross margin decreased from 24.8% in fiscal year 1994 to
21.9% in fiscal year 1995, due primarily to changes in the product mix to
lower-margin products, including an increase of the percentage of manufacturing
revenues derived from products in preproduction. Engineering gross margin as a
percentage of engineering revenues increased from 5.6% in fiscal year 1994 to
8.0% in fiscal year 1995 for the reasons stated above.
Marketing, General and Administrative Expenses
The following table sets forth marketing, general and administrative
expenses with the corresponding percentage of revenues for the fiscal years
indicated.
<TABLE>
<CAPTION>
YEAR ENDED JUNE 30,
- -------------------------------------------------------------------------
1994 1995 1996
- --------------------- --------------------- ---------------------
MG&A % OF MG&A % OF MG&A % OF
EXPENSES REVENUES EXPENSES REVENUES EXPENSES REVENUES
- -------- -------- -------- -------- -------- --------
(dollars in thousands)
<S> <C> <C> <C> <C> <C>
$1,818 12.4% $1,931 10.9% $2,938 11.3%
</TABLE>
Marketing, general and administrative expenses increased by approximately
$1.0 million from fiscal year 1995 to fiscal year 1996, due primarily to
increased Company-wide bonuses and increased management information systems
costs. Marketing, general and administrative expenses before bonuses represented
10.0% and 8.5% of revenues in fiscal years 1995 and 1996, respectively, as fixed
costs were spread over a higher revenue base. If anticipated revenue growth
occurs, SeaMED expects marketing, general and administrative expenses as a
percentage of revenues to decline in the near term.
Marketing, general and administrative expenses did not change significantly
from fiscal year 1994 to fiscal year 1995 because the number of employees in the
relevant departments remained substantially the same.
23
<PAGE> 24
Marketing, general and administrative expenses before bonuses represented 11.7%
of revenues in fiscal year 1994.
Operating Income
The following table sets forth operating income with the corresponding
operating margin as a percentage of revenues and the year-to-year percentage
increase for the fiscal years indicated.
<TABLE>
<CAPTION>
YEAR ENDED JUNE 30,
- ---------------------------------------------------------------------------------------------------------
1994 1995 1996
- ----------------------- ----------------------- -----------------------
OPERATING OPERATING OPERATING OPERATING % OPERATING OPERATING %
INCOME MARGIN INCOME MARGIN INCREASE INCOME MARGIN INCREASE
- --------- --------- --------- --------- -------- --------- --------- --------
(dollars in thousands)
<S> <C> <C> <C> <C> <C> <C> <C>
$ 937 6.3% $ 1,140 6.5% 21.6% $ 2,100 8.0% 84.2%
</TABLE>
The $960,000 increase in operating income from fiscal year 1995 to fiscal
year 1996 is due primarily to an increase in both manufacturing volume and the
manufacturing gross margin percentage. In addition, engineering volume and gross
margins improved. These improvements were offset by the increase in marketing,
general and administrative expenses, the most significant of which was the
Company-wide bonus.
The increase in operating income from fiscal year 1994 to fiscal year 1995
was due primarily to increased revenues.
Income Taxes
The Company's effective tax rate was 35% in fiscal year 1996 and 18.9% in
fiscal year 1995. A tax benefit of $208,500 was recorded in fiscal year 1994.
Differences from the federal statutory income tax rate of 34% for fiscal years
1994 and 1995 resulted primarily from the use of net operating loss
carryforwards and tax credits and the reversal of valuation allowances due to
changes in the estimate of realizable deferred tax assets. The Company expects
the future effective tax rate to stabilize at a rate that approximates the
federal statutory rate of 35%.
QUARTERLY OPERATING DATA
Changes in customer orders have had a significant effect on SeaMED's
results of operations. The volume and timing of customer orders may vary due to
(i) variation in demand for customer products as a result of, among other
things, product life cycles, competitive conditions and general economic
conditions, (ii) the customer's attempt to balance its inventory, (iii) the
customer's need to adapt to changing regulatory conditions and requirements, and
(iv) changes in the customer's manufacturing strategy. Production may be reduced
or discontinued at any time, causing sales fluctuations from quarter to quarter.
SeaMED's business organization and its related cost structure anticipate
supporting a certain minimum level of revenues. The Company, therefore, has a
limited ability to adjust its short-term cost structure, which compounds
quarterly fluctuations.
24
<PAGE> 25
The following table sets forth unaudited revenues, operating income, net
income (loss) and fully diluted net income per share of SeaMED for each of the
quarters for the fiscal years ended June 30, 1995 and 1996 and for the first
quarter of fiscal year 1997, which ended on September 30, 1996. In the opinion
of management, the data include all adjustments, consisting only of normal
recurring adjustments, necessary to present fairly the information set forth
therein.
<TABLE>
<CAPTION>
FISCAL YEAR 1995 FISCAL YEAR 1996 FISCAL YEAR 1997
------------------------------------- ------------------------------------- ----------------
FIRST SECOND THIRD FOURTH FIRST SECOND THIRD FOURTH FIRST
QUARTER QUARTER QUARTER QUARTER QUARTER QUARTER QUARTER QUARTER QUARTER
------- ------- ------- ------- ------- ------- ------- ------- ----------------
<S> <C> <C> <C> <C> <C> <C> <C> <C> <C>
(dollars in thousands, except per share amounts)
Revenues................ $4,452 $3,635 $4,560 $5,014 $5,000 $5,366 $7,040 $8,724 $ 10,076
Operating income........ 359 54 423 304 302 334 644 820 838
Net income (loss)....... 249 (2) 316 212 167 182 395 496 487
Fully diluted net income
per share............. $ 0.07 -- $ 0.08 $ 0.05 $ 0.04 $ 0.05 $ 0.10 $ 0.13 $ 0.12
</TABLE>
The Company's quarterly results may fluctuate significantly, and the
results for the first quarter of fiscal year 1997 are not necessarily indicative
of the results that may be expected for the entire fiscal year.
LIQUIDITY AND CAPITAL RESOURCES
SeaMED has historically financed its operations through earnings, debt and
sales of securities. Net cash provided by operating activities was approximately
$658,000 in fiscal year 1995 compared to net cash used in operating activities
of approximately $296,000 in fiscal year 1996, with the change being due
primarily to the need to use increased fiscal year 1996 earnings to finance a
large increase in working capital. Net cash used in operating activities was
$1.0 million in fiscal year 1994 compared to net cash provided by operating
activities of $658,000 in fiscal year 1995, with the change being due primarily
to a smaller increase in inventory and accounts receivable in fiscal year 1995.
SeaMED has a zero-balance cash management arrangement with Pacific
Northwest Bank (the "Bank"). Under this arrangement, the amount outstanding
under SeaMED's line of credit fluctuates daily based on the Company's receipts
and disbursements. Under the line of credit, SeaMED can borrow up to 80% of
eligible accounts receivable (less than 60 days outstanding) to a maximum of
$4.0 million. Borrowings under the line bear interest at the Bank's prime rate
plus .25% (8.5% at September 30, 1996) and are secured by receivables and
inventories. The line is subject to annual approval and extension by December 1
of each year. At September 30, 1996, SeaMED had drawn approximately $2.2 million
against the $4.0 million limit.
In addition to the line of credit, SeaMED has three notes payable to the
Bank, each of which requires monthly payments including interest and is secured
by a lien on the Company's equipment. One such note bears interest at a rate of
8.5%, requires monthly payments of approximately $19,000, is due on August 5,
1998, and at September 30, 1996 had an outstanding balance of approximately
$392,000. The second such note bears interest at a rate of 8.75%, requires
monthly payments of approximately $15,000, is due on November 5, 1999, and at
September 30, 1996 had an outstanding balance of approximately $492,000. The
third such note bears interest at a rate of 8.75%, requires monthly payments of
approximately $12,000, is due on July 5, 2000, and at September 30, 1996 had an
outstanding balance of approximately $484,000.
At September 30, 1996, total indebtedness to the Bank, including the line
of credit and the three notes payable, was approximately $3.6 million. SeaMED
anticipates using a portion of the net proceeds of this offering to repay all
outstanding indebtedness to the Bank.
In addition to borrowings from the Bank, SeaMED also has an unsecured
subordinated note payable to Cordis Corporation, with an interest rate
adjustment on each July 1 to the prime rate plus 2% (10% at September 30, 1996),
with a maximum rate of 10% and a minimum rate of 7%. The note is due in monthly
payments of $17,000 through May 2001. At September 30, 1996, the balance
outstanding on this note was approximately $751,000.
25
<PAGE> 26
SeaMED expects to use a portion of the net proceeds of this offering to pay
a cumulative preferred dividend of approximately $1.8 million, to fund working
capital needs and for general corporate purposes, including leasehold
improvements and purchases of equipment. The Company, if the opportunity arises,
may use an unspecified portion of the net proceeds to acquire other
manufacturing or engineering businesses or assets that complement the Company's
existing business. The Company currently is not engaged in any discussions
regarding such acquisitions and has no plans, arrangements, understandings or
agreements regarding any specific acquisition.
SeaMED believes that the net proceeds of this offering, together with
existing capital resources and amounts available under its existing line of
credit with the Bank, will satisfy the Company's anticipated capital needs for
the next 12 to 24 months (depending primarily on SeaMED's growth rate and its
results of operations). To accommodate anticipated future growth, SeaMED will
need additional sources of capital to fund working capital needs for inventory
and accounts receivable, to lease and acquire equipment for additional plant
facilities and to make other capital expenditures. Capital expenditures were
$876,000 in fiscal year 1994, $1.2 million in fiscal year 1995 and $1.5 million
in fiscal year 1996. Management currently projects that capital expenditures
will be approximately $2.0 million in fiscal year 1997. Following this offering,
SeaMED will review the adequacy of its line of credit.
SeaMED leases two buildings under long-term leases with an aggregate of
approximately 81,000 square feet, which require annual lease payments of
approximately $900,000. In September 1996, SeaMED entered into a lease for an
additional 90,000 square feet of space for a term of 10 years with two five-year
renewal options. When fully occupied (anticipated to be by January 1, 1999), the
annual lease payment on this space will be approximately $1.2 million.
There can be no assurance that appropriate sources of capital will be
available in the future or, if available, will be on terms acceptable to the
Company. See "Risk Factors -- Future Capital Requirements."
26
<PAGE> 27
BUSINESS
INTRODUCTION
SeaMED manufactures advanced durable electronic medical instruments for
medical technology companies, often as part of systems that also include
single-use components. To assist its customers in developing and commercializing
their instruments for manufacture by SeaMED, the Company provides a wide range
of engineering services and regulatory expertise. In its last fiscal year,
SeaMED manufactured or engineered medical instruments for many established
medical technology companies, including Boston Scientific Corporation, C. R.
Bard, Inc., Guidant Corporation, Marquette Electronics, Sorin Biomedical Inc.
and St. Jude Medical, Inc. SeaMED's customers also include many emerging medical
technology companies such as ArthroCare Corporation, CellPro, Incorporated,
Gynecare, Inc., ReSound Corporation and Urologix, Inc. Of these established and
emerging companies, Boston Scientific Corporation (through two subsidiaries) and
C. R. Bard, Inc. each represented in excess of 10% of SeaMED's revenues for
fiscal year 1996, each of two such companies represented between 5% and 10% of
such revenues, and each of the remaining companies represented less than 5% of
such revenues. SeaMED has ongoing contracts with respect to each of such
established and emerging companies, except that SeaMED manufactures on a
purchase order basis but does not have ongoing contracts with E. P.
Technologies, Inc. (a subsidiary of Boston Scientific Corporation), C. R. Bard,
Inc., Guidant Corporation, Marquette Electronics, Resound Corporation, Sorin
Biomedical Inc. and St. Jude Medical, Inc. See "-- Manufacturing Operations."
SeaMED's revenues have grown from $8.7 million in fiscal year 1992 to $26.1
million in fiscal year 1996, a compound annual growth rate of 32%, and its
operating income has grown from $807,000 in fiscal year 1992 to $2.1 million in
fiscal year 1996, a compound annual growth rate of 27%. During this period, the
number of manufactured instruments grew from seven to 23.
Since 1988, SeaMED has focused its business primarily on manufacturing
medical instruments and believes it is the largest independent manufacturer of
advanced medical instruments for medical technology companies. As part of its
growth strategy, SeaMED continues to expand its engineering expertise,
regulatory knowledge and manufacturing capabilities, thereby allowing it to
design and manufacture a broader range of medical instruments. SeaMED also
utilizes its existing resources and expertise by accepting high value-added
engineering and manufacturing contracts for select nonmedical products.
INDUSTRY OVERVIEW
Demand for health care has grown rapidly in recent years, and is expected
to continue to increase as the population ages. Advancements in science,
medicine, and computers have dramatically expanded the number and variety of
effective medical procedures. The most advanced medical procedures and
techniques, many of which use advanced medical instruments, now are common
treatments under many health insurance plans. As insurance companies and federal
and state governments have expanded the medical procedures for which health care
providers would be reimbursed, demand has grown for the medical instruments and
systems needed for these procedures. More recently, in response to increasing
pressure to control rising health care costs, medical technology companies have
developed advanced medical instruments and systems that improve patient outcomes
and lessen the overall cost of health care by reducing palliative care and acute
hospital stays.
As medical products have incorporated the latest developments in computers,
electronics, materials and other technologies, the cost of product development
and the length of the development cycle have increased substantially. The risks
in developing and launching new medical products also have increased
significantly as competition in the highly fragmented medical technology
industry has increased. As a result, medical technology companies face increased
pressure to bring new products to market in the shortest possible time, reduce
costs, maintain or increase market share and accelerate realization of revenue.
At the same time, the FDA and the European Community have adopted
increasingly stringent and evolving regulatory requirements for the manufacture
of medical products. In the United States, certain medical products are subject
to the FDA's PMA requirements and many medical products require premarket
clearance. In addition, products are subject to regulation with respect to
manufacture, labeling, distribution, postmarket reporting and promotion. Under
European quality standards to be effective in 1998, the design of medical
products must satisfy specific engineering design process standards. To market
and sell their products, medical technology companies must invest significant
financial resources to establish and maintain manufacturing facilities that
comply with the FDA's GMP requirements and the European Community's quality
system standards, particularly if the facilities produce life-supporting,
life-sustaining, or implantable products. After the often lengthy and
time-consuming process of obtaining FDA marketing authorization and ISO
certification, medical technology companies must devote substantial managerial
oversight to ensure continued compliance with FDA and European Community
requirements.
27
<PAGE> 28
SeaMED believes that the trend toward outsourcing medical product
engineering and manufacturing is in its early stages and outsourcing revenues
represent a very small percentage of the more than $30 billion medical
technology industry. SeaMED also believes that medical technology companies will
expand their outsourcing of engineering and manufacturing and that SeaMED is
well positioned for such expansion. With intensified competition, higher initial
product development costs and longer product development and regulatory cycles,
many of SeaMED's customers have chosen to concentrate product development and
manufacturing resources on higher-volume single-use components and to outsource
the development and manufacturing of durable medical instruments.
THE SEAMED ADVANTAGES
SeaMED provides integrated solutions to the engineering, regulatory and
manufacturing challenges of advanced medical instruments. SeaMED offers its
customers the following advantages:
- Broad Experience With Numerous Advanced Medical Instruments. Since
1992, SeaMED has manufactured 21 different advanced medical
instruments that incorporate diverse technologies, and it currently
has an additional 14 instruments or systems in the engineering design
phase. As a result, SeaMED has developed considerable expertise in
solving its customers' product development, engineering,
manufacturing and regulatory issues.
- Focus on Core Functions. By relying on SeaMED's engineering and
manufacturing capabilities, customers can focus management efforts on
product research, clinical development and sales and marketing, as
well as manufacturing their higher-volume, single-use components. In
addition, SeaMED's customers can shift to variable costs the high
fixed costs associated with staffing and maintaining GMP compliant
facilities for durable medical instruments.
- Production Flexibility. SeaMED's broad customer base permits it to
offer its customers production flexibility, which enables customers
to adjust production volumes in response to fluctuations in market
demand or regulatory issues.
- Rapid Product Development. SeaMED believes that, with its engineering
and manufacturing capabilities, it can more rapidly develop and
manufacture new products at a lower overall cost than its customers,
which otherwise expend significant time and financial resources to
develop internal engineering expertise, establish GMP-qualified
manufacturing facilities and obtain ISO certification.
- Regulatory Compliant Manufacturing. SeaMED's medical manufacturing
facilities are ISO 9001/EN 46001 certified and SeaMED believes that
they comply with GMP requirements. SeaMED currently manufactures six
medical instruments that are regulated as Class III instruments,
which is the most stringent FDA regulatory category. Due to the
critical nature of regulatory compliance, SeaMED devotes significant
management time and financial resources to GMP compliance and ISO
certification.
- Integrated Engineering and Manufacturing. SeaMED provides a wide
range of engineering services, and has the capabilities to provide
complete instrument or system design (including engineering, testing,
component analysis and regulatory compliance), which enhances its
manufacturing business. By integrating engineering design work with
manufacturing processes, materials acquisitions and quality and
regulatory considerations, SeaMED believes that it can increase the
quality and lower the overall cost of the instruments that it
manufactures for its customers. Since 1992, SeaMED's engineering
staff has performed substantially all the engineering design work for
15 medical instruments.
CUSTOMERS AND PRODUCTS
SeaMED's customers include some of the world's largest medical technology
companies as well as many emerging medical technology companies. As of September
30, 1996, SeaMED was manufacturing 18 medical instruments for 18 customers and
was engaged in the engineering design phase of 14 instruments for 11
28
<PAGE> 29
customers. In fiscal year 1996, revenues from two customers, Boston Scientific
Corporation (through two subsidiaries) and C. R. Bard, Inc., each accounted for
more than 10% of the Company's revenues. SeaMED negotiates separate contracts
with its customers for engineering design services and product manufacturing.
Most projects begin with an engineering design contract. As a business strategy,
SeaMED generally prices engineering contracts to cover direct project expenses
(i.e., nonrecurring engineering expenses) plus a share of operating expenses.
SeaMED's objective is to obtain the exclusive manufacturing rights to medical
instruments for a specific time period, generally three to five years. SeaMED
believes that no customer has replaced SeaMED as its manufacturer.
The following list identifies for fiscal year 1996 all manufacturing
customers with medical instruments manufactured by SeaMED, except two customers
that contributed revenues of less than $100,000 in the aggregate, and indicates
whether the instrument (i) has not received regulatory approval in the United
States ("U.S. Precommercial"), (ii) is being manufactured for sale and
distribution in the United States ("U.S. Commercialized"), or (iii) is being
manufactured for export outside the United States ("International
Commercialized"). The Company realized engineering revenues in fiscal year 1996
from all but two of the customers listed below.
<TABLE>
<CAPTION>
- --------------------------------------------------------------------------------------------------------
INSTRUMENT STATUS
----------------------------------------------
U.S.
------------------------------ INTERNATIONAL
CUSTOMER INSTRUMENT DESCRIPTION PRECOMMERCIAL COMMERCIALIZED COMMERCIALIZED
---------------------------- -------------- -------------- --------------
<S> <C> <C> <C> <C> <C>
ArthroCare Corporation.... Power console for
arthroscopic ablation
system...................... X X
Boston Scientific
Corporation:
EP Technologies,
Inc.................. RF generator for
electrophysiology ablation
system...................... X X
Heart Technology,
Inc.................. Drive console for
atherectomy system.......... X X
C. R. Bard, Inc........... Amplifier for
electrophysiology........... X X
Monitor for urinary output
and core temperature........ X X
CellPro, Incorporated..... Stem cell separator......... X X
Guidant Corporation:
Cardiac Pacemakers,
Inc.................. Pacemaker system analyzer... X X
Gynecare, Inc............. Power console for
endometrial ablation
system...................... X X
Marquette Electronics:
E for M................ Amplifier for
electrophysiology........... X X
ReSound Corporation....... Hearing aid programmer...... X X
Sorin Biomedical Inc...... Control console for
cardioplegia system......... X X
St. Jude Medical, Inc.:
Pacesetter, Inc........ Pacemaker system analyzer... X X
Urologix, Inc............. Power control console for
transurethral thermal
therapy system.............. X X
- -------------------------------------------------------------------------------------------------------------
</TABLE>
SeaMED from time to time selectively designs and manufactures nonmedical
commercial products that benefit from SeaMED's engineering and manufacturing
capabilities. Currently, SeaMED manufactures one such product, a coin-counting
machine that exchanges loose coins for currency, for Coinstar which represented
approximately 25% of SeaMED's revenues for the quarter ended September 30, 1996.
SeaMED currently manufactures these machines under a one-year nonexclusive
manufacturing agreement with Coinstar that allows Coinstar to cancel or modify
orders with SeaMED on 90 days' notice, except for product orders scheduled for
delivery within 90 days. Under the terms of the agreement, in the event that
Coinstar cancels product orders, Coinstar has agreed to reimburse SeaMED for
certain raw material and related costs. SeaMED believes its experience in
manufacturing the large and complex Coinstar machine has expanded its
29
<PAGE> 30
manufacturing expertise. SeaMED also has one engineering contract to design one
other nonmedical product. SeaMED intends to maintain as its primary focus the
design and manufacturing of advanced medical instruments for medical technology
companies. See "Risk Factors -- Customer Concentration" and "-- Management of
Growth."
ENGINEERING
SeaMED will provide its customers with engineering services at any stage of
an instrument's development. Customers in many cases rely on SeaMED for complete
instrument design (including engineering, testing, component analysis and
regulatory compliance). Since 1992, SeaMED's engineering staff has performed
substantially all of the engineering design work for 15 instruments. Customers,
however, often deliver final drawings for instruments they believe ready for
manufacturing. In such cases, SeaMED reviews and tests the existing design prior
to manufacturing the instrument and, in many cases, SeaMED's engineers are able
to identify and offer alternatives to the customer's design that improve
performance or produce manufacturing efficiencies.
SeaMED approaches each engineering project using a team structure, each
team being a multi-disciplinary collection of engineers and technicians who
understand the technical requirements of the particular project. Each team
includes representatives from other engineering disciplines, including one or
more manufacturing, test and quality engineers, who help design an instrument
that can be manufactured in a manner that meets or exceeds customer
specifications and applicable regulatory requirements.
SeaMED integrates its engineering staff throughout its operations,
including sales and marketing, customer relations, materials management, quality
assurance, regulatory compliance and manufacturing. SeaMED's engineers play a
critical role in sales and marketing by assisting SeaMED's Vice President, Sales
and Marketing, in evaluating requests for proposals and developing
project-specific, solution-oriented responses, bids, cost estimates and project
plans. Similarly, SeaMED project engineers act as customer contacts throughout
the engineering design phase and have responsibility for all aspects of a
customer's project, including coordinating the component parts necessary for the
instrument, quality assurance procedures, regulatory compliance and the
manufacturing process. SeaMED provides its customers with design information and
other support during the 510(k) approval or PMA process, but does not assist in
the testing, studies and human clinical trials associated with these processes.
SeaMED provides testing services in the area of safety regulation, such as those
necessary to obtain a listing by Underwriters Laboratories, Inc. SeaMED has made
significant investments in state-of-the-art equipment to support its engineering
design effort, including engineering design and testing stations and
computer-aided design software.
Each instrument, product design, patent and other proprietary right
developed by SeaMED becomes the property of the customer, with SeaMED typically
retaining the manufacturing rights to such instrument for a period generally
ranging from three to five years. Generally, SeaMED provides nonrecurring
engineering services under a project plan that identifies the engineering tasks,
deliverables and schedule. Typically, such services are billed on a time and
materials basis and are cancelable at any time. The project plan usually states
that SeaMED is intended to be the manufacturer of the instrument, but does not
specify the manufacturing terms. SeaMED typically provides a design defect
warranty for 15 months to replace or repair instruments relating to the specific
elements for which SeaMED had primary design responsibility.
At September 30, 1996, SeaMED's engineering staff consisted of 56 engineers
employed by SeaMED and 19 consulting or contract engineers. The engineering
staff includes a variety of disciplines, as follows:
<TABLE>
<CAPTION>
ENGINEERING CATEGORY NUMBER
-------------------------------------------- ------
<S> <C>
Component................................... 2
Electrical Design........................... 14
Electrical Test............................. 9
Manufacturing............................... 14
Mechanical Design........................... 19
Reliability and Quality..................... 10
Software Design............................. 7
--
Total............................. 75
</TABLE>
30
<PAGE> 31
MANUFACTURING OPERATIONS
As the engineering project nears completion, the members of the project
team with direct responsibility for manufacturing, quality assurance,
manufacturing/test engineering and materials assume a greater role. The team
implements a materials management system and develops an assembly process and
product testing and quality assurance procedures to produce high-quality
instruments that satisfy customer specifications as well as GMP and ISO 9001
quality standards. Often, manufacturing begins with a relatively small number of
preproduction units, which are used by the customer for clinical trials. SeaMED
and the customer frequently make engineering and manufacturing refinements
during the preproduction phase.
Each instrument is manufactured in a dedicated manufacturing cell on the
Company's manufacturing floor. At September 30, 1996, SeaMED had 19 cells in
operation. These cells are flexible and can be expanded or modified as needed,
enabling SeaMED to adjust production volumes quickly in response to customer
orders.
SeaMED's customers generally submit purchase orders for delivery of
instruments in future periods. As of September 30, 1995 and September 30, 1996,
customers had placed purchase orders with SeaMED for future deliveries totaling
$7.2 million and $23.0 million, respectively, with all such deliveries scheduled
to occur before the end of the respective fiscal year. The Company does not
regard backlog data as a meaningful indicator of revenues for future periods
because of its policy of generally allowing its customers to cancel orders at
any time without notice.
SeaMED uses a fully integrated materials requirements system. This system,
which includes sales order entry, purchasing, inventory control, production
control, and cost accounting, helps SeaMED manage material acquisitions and
inventory for the various projects in full production at any one time and
facilitates the planning and control essential to building products within
critical time schedules.
Manufacturing contracts are generally executed near completion of the
engineering project, at which time SeaMED and the customer negotiate the term,
pricing, warranty, indemnity and other provisions. Pricing typically is based on
SeaMED's expected cost and an agreed-upon margin, both of which are subject to
customer audit. Although manufacturing contracts rarely include minimum
production requirements, they typically grant SeaMED exclusive manufacturing
rights for periods generally ranging from three to five years. Contracts
typically are terminable only for cause, which generally is defined as the
failure to deliver instruments on a timely basis or the failure to comply with
design specifications. In each case, SeaMED usually has an opportunity to cure
the breach. SeaMED generally warrants conformity to design specifications and
against defects in materials and workmanship and indemnifies its customers
against losses arising out of a breach of such warranty. In addition, SeaMED in
many cases enters into repair and service agreements with its customers that set
forth the pricing and terms under which SeaMED provides repair and replacement
parts, and needed services and upgrades not covered under warranty. Although
most of SeaMED's manufacturing is performed under long-term manufacturing
contracts, seven instruments, with revenues for the fiscal year ended June 30,
1996 totaling approximately $8.3 million, are manufactured only under purchase
orders. SeaMED, however, currently is negotiating master manufacturing contracts
with customers of four of such instruments.
QUALITY ASSURANCE AND REGULATORY COMPLIANCE
SeaMED emphasizes quality throughout its operations and integrates its
quality assurance and quality engineering programs throughout each instrument's
engineering and manufacturing phases, a process that involves SeaMED's senior
management and executive officers. At September 30, 1996, SeaMED employed 37
personnel in its quality assurance, quality engineering and regulatory
departments, 10 of whom are engineers.
Quality assurance procedures are integrated into every aspect of an
instrument's manufacturing cycle. SeaMED establishes a quality assurance program
for each instrument, which includes a "zero defects" objective. Substantially
all component parts and outside-contracted product subassemblies receive a
control number and are inspected and, if necessary, tested. SeaMED requires all
vendors that supply components to satisfy certain quality standards. On the
manufacturing floor, quality assurance personnel implement quality
31
<PAGE> 32
procedures at interim points during the assembly process and conduct a
final-level test when the instrument is fully assembled and ready for shipping.
In addition, prior to shipping, a quality inspector reviews each instrument for
proper labeling and paperwork.
SeaMED is registered with the FDA as a medical device manufacturer. As a
manufacturer of instruments reviewed under the PMA process, SeaMED is subject to
inspections by the FDA prior to PMA approval. SeaMED has experienced regularly
scheduled and unscheduled FDA audits in past years, none of which required
significant changes to its facilities or processes and none of which required
discontinuation of normal operations. See "-- Governmental Regulation."
In 1994, SeaMED received ISO 9001/EN 46001 certification. ISO 9000 is the
first quality system standard to gain worldwide recognition, including in the
European Community, Japan and the United States. As many medical technology
companies expand sales of products in international markets, compliance with
international quality standards has increased in importance. SeaMED's ISO 9001
designation is the highest level of ISO 9000 certification and indicates that
SeaMED has met design, manufacture and test standards for its products. SeaMED's
EN 46001 designation indicates that it has met additional standards specific to
medical instruments.
SeaMED's ISO 9001/EN 46001 certification serves as a marketing tool that
enhances SeaMED's competitive position in the industry, especially with respect
to medical technology companies with internal manufacturing facilities that have
not gone through the costly and time-consuming ISO certification process.
SALES AND MARKETING
SeaMED generates new business opportunities by promoting its engineering
design and manufacturing capabilities at industry trade shows, by advertising in
leading industry publications, and by obtaining referrals from customers, former
employees of customers and other parties familiar with SeaMED's services. While
SeaMED's sales and marketing department consists solely of the Vice President,
Sales and Marketing, other executive officers and project engineers participate
extensively in sales and marketing activities. SeaMED believes it can
effectively market and sell its engineering and manufacturing capabilities while
maintaining a small sales and marketing staff.
COMPETITION
For established medical technology companies, SeaMED's primary competitor
is the internal design and manufacturing facilities of its prospective customer.
For emerging companies, SeaMED competes both with the customer's internal design
and manufacturing facilities (planned or operational), other manufacturers that
operate in the medical technology industry and, to a lesser extent, with
specialty design firms, most of which do not have manufacturing capabilities.
The primary competitive factors in medical instrument design and manufacturing
include quality, regulatory compliance, technical engineering competence, cost
of the nonrecurring engineering design component, price of the manufactured
product, experience, customer service, and ability to meet a design and
production schedule.
Competition is primarily limited to those companies that meet the minimum
applicable regulatory requirements of the FDA and international manufacturing
and design standards. In the future, SeaMED is likely to compete against new
entrants into the industry as outsourcing expands in medical technology
products. For example, medical technology companies with design and
manufacturing capabilities (especially those with excess capacity) and large
electronic contract manufacturers and defense department contractors with
extensive nonmedical engineering expertise may undertake design and/or
manufacture of medical instruments. Although SeaMED is not aware of substantial
competition from these sources to date, there can be no assurance that these, or
other formidable, competitors will not aggressively expand into SeaMED's
targeted market segment in the future.
32
<PAGE> 33
GOVERNMENTAL REGULATION
SeaMED's business and operations are subject to substantial governmental
regulation, primarily from the FDA in the United States and the regulatory
bodies in other countries, as described below. While these regulations directly
affect SeaMED's design and manufacturing operations, to a greater extent they
affect SeaMED's customers and their products. To the extent that production of a
customer's instrument is delayed or cancelled due to regulatory noncompliance,
the timing and levels of revenues received by SeaMED may be affected adversely.
United States
Because SeaMED provides design and manufacturing services to producers of
medical devices, SeaMED's manufacturing facilities are subject to extensive
regulation by the FDA under the FDC Act. Manufacturers of medical devices must
comply with applicable provisions of the FDC Act and associated regulations
governing the development, testing, manufacturing, labeling, marketing and
distribution of medical devices and the reporting of certain information
regarding their safety. The FDC Act requires PMA approval before certain medical
devices can be marketed.
The FDA classifies medical devices into three classes (Class I, II or III)
on the basis of the controls deemed necessary by the FDA to reasonably ensure
product safety and efficacy. Class I devices are subject to general controls
(e.g., labeling, premarket notification and adherence to GMP) and Class II
devices are subject to general and special controls (e.g., performance standards
and guidelines). Generally, Class III devices are higher-risk devices and cannot
be marketed until after receiving FDA PMA approval. Currently, 12 instruments of
SeaMED's customers are Class III devices that require PMA approval prior to
commercialization, two of which have received such approval.
A premarket approval application must be supported by valid scientific
evidence, which typically includes extensive data, including preclinical and
clinical trial data to demonstrate safety and efficacy of the device. The
application also must contain the results of all relevant bench tests,
laboratory and animal studies, a complete description of the instrument and its
components, and a detailed description of the methods, facilities and controls
used to manufacture the device. In addition, the submission must include the
proposed labeling. Although SeaMED's services do not extend to assistance with
testing, studies and human clinical trials, SeaMED does provide its customers
with required design information and other support during the PMA process.
Typically, the FDA will inspect the manufacturer prior to granting PMA approval.
If the FDA identifies deficiencies in the manufacturing process, it could delay
PMA approval. Delays in the PMA process can affect the timing of manufacturing
services provided by SeaMED. Currently, an FDA review of a PMA application
generally takes one to two years from the date the application is submitted, but
often is significantly extended by an FDA request for more information or
clarification of information previously submitted. The PMA process can be
expensive, uncertain and lengthy, and a number of devices for which PMA approval
has been sought have never been approved for marketing. Until a device subject
to the PMA requirement receives PMA approval, it cannot be sold commercially in
the United States. After PMA approval is obtained, subsequent modifications to
the device, its labeling or manufacturing may require additional FDA approvals.
For Class I and Class II devices, and certain Class III devices, FDA
clearance may be obtained through a 510(k) notification, pursuant to which the
FDA determines that a medical device is "substantially equivalent" to an
existing, legally marketed predicate device or a predicate device marketed
before May 28, 1976. Clinical testing of certain devices may be required as part
of the 510(k) process. Currently, five of SeaMED's customers have submitted or
intend to submit a request to the FDA for clearance for marketing under a 510(k)
notification for devices to be manufactured by SeaMED. There can be no assurance
that the FDA will find a device substantially equivalent and allow marketing of
such device. Even if the device is found substantially equivalent, the clearance
process may be delayed.
Any instrument manufactured by SeaMED or distributed by its customers
pursuant to FDA clearances or approvals is subject to pervasive and continuing
regulation by the FDA, including record-keeping requirements and reporting of
adverse experiences associated with the use of the instrument. Device
33
<PAGE> 34
manufacturers are required to register their establishments and list their
devices with the FDA and certain state agencies, and are subject to periodic
inspections by the FDA and certain state agencies. The FDC Act requires devices
to be manufactured in accordance with GMP regulations, which impose certain
procedural and documentation requirements upon SeaMED with respect to
manufacturing and quality assurance activities. The FDA has changed the GMP
regulations. Among other things, the new regulations will require design
controls and maintenance of service records. SeaMED believes that the new
regulations will not substantially increase SeaMED's cost of complying with GMP
requirements. SeaMED currently has implemented training and procedural changes
with respect to the changes to GMP. Noncompliance with FDA regulations can
result in, among other things, SeaMED and its customer's being subject to fines,
injunctions, civil penalties, criminal prosecution, recall or seizure of
devices, total or partial suspension of production, failure of the government to
grant premarket clearance or PMA approval for products, withdrawal of marketing
approvals, or a recommendation by the FDA that a customer not be permitted to
enter into government contracts. The FDA also has the authority to require
repair, replacement or refund of the cost of any device manufactured or
distributed by a customer of SeaMED. In addition, the failure to be found in
compliance with the FDA regulations could have an adverse effect on the
Company's reputation. The FDA periodically inspects device manufacturers for
compliance with FDA regulations. In addition, the FDA generally inspects a
manufacturer prior to approving a PMA. There can be no assurance that the
Company will be found in compliance with all applicable regulations during such
an inspection. The failure to be found in compliance with the GMP regulations
would result in FDA enforcement action against the Company, which could result
in a diminution of the Company's reputation and an adverse effect on the
Company's business, results of operations and financial condition.
International
Sales of medical devices outside the United States are subject to
regulatory requirements that vary from country to country. The time required to
obtain approval for sale in foreign countries may be longer or shorter than that
required for FDA approval, and the requirements may differ. The export of
devices is subject to FDA regulation. In some instances, prior FDA approval is
needed. Commencing in 1998, all medical device manufacturers will be required to
obtain certifications necessary to enable the CE mark to be affixed to their
products sold in the European Community. SeaMED received in, and has maintained
since, June 1994 ISO 9001/EN 46001 certification. If a SeaMED customer is also
ISO 9001 certified, the customer may be permitted to affix the CE mark to an
instrument manufactured by SeaMED without the customer being subject to
additional requirements. In addition, all medical device manufacturers must
comply with other laws generally applicable to foreign trade, including
technology export restrictions, tariffs and other regulatory barriers.
EMPLOYEES AND LABOR RELATIONS
As of September 30, 1996, SeaMED employed a total of 226 people and
retained 60 consulting or contract personnel in the following areas:
<TABLE>
<CAPTION>
CATEGORY NUMBER
-------------------------------------------------------------------- ------
<S> <C>
Design and Engineering.............................................. 88
Preproduction and Manufacturing..................................... 142
Quality Assurance................................................... 37
Sales and Marketing, Financing and Administration................... 19
---
Total..................................................... 286
</TABLE>
SeaMED considers its labor relations to be good and none of its employees
are covered by a collective bargaining agreement.
PROPERTIES
SeaMED leases three buildings, two of which are under long-term leases
aggregating approximately 81,000 square feet. The third lease is for a building
with approximately 7,800 square feet, and expires in June 1997. The current
facilities are located in Redmond, Washington. Of the approximately 88,000
square
34
<PAGE> 35
feet currently occupied by SeaMED, approximately 50,000 square feet are used for
manufacturing, approximately 28,000 square feet are used for engineering
(including the entire 7,800 square feet held pursuant to the lease expiring in
June 1997) and approximately 10,000 square feet are used for administrative
purposes.
In September 1996, the Company entered into lease agreements to occupy
90,000 square feet of production space in two new buildings. The Company will
occupy the first 30,000 square feet on May 1, 1997, the second 30,000 square
feet on February 1, 1998 and the third 30,000 square feet on January 1, 1999.
The lease term is 10 years with two five-year renewal options. Based on
anticipated growth in the number and size of manufacturing cells, SeaMED intends
to move substantially all of the manufacturing of commercialized instruments to
the 90,000 square feet of space in the two new buildings. The 81,000 square feet
in the two buildings currently occupied under long-term leases are expected to
serve SeaMED's administrative and engineering needs, as well as provide
manufacturing space for instruments in the early stages of preproduction.
LEGAL PROCEEDINGS
There are no pending legal proceedings to which SeaMED is a party or to
which any of its property is subject.
35
<PAGE> 36
MANAGEMENT
EXECUTIVE OFFICERS AND DIRECTORS
The names, ages and positions of the executive officers and directors of
the Company as of September 30, 1996 are listed below.
<TABLE>
<CAPTION>
NAME AGE POSITION
- ---------------------------- --- ---------------------------------------------------------
<S> <C> <C>
W. Robert Berg.............. 53 President, Chief Executive Officer and Director(1)
Edgar F. Rampy.............. 57 Vice President, Treasurer and Chief Financial Officer
Donald Rich................. 45 Vice President, Operations
Thomas F. Mrowca............ 47 Vice President, Sales and Marketing
Marcia A. Page.............. 37 Vice President, Quality Assurance and Regulatory Affairs
S. Erik Hagstrom............ 41 Vice President, Engineering
R. Scott Asen............... 52 Chairman of the Board(1)(2)(3)
Stephen J. Clearman......... 45 Director(1)(2)
William D. Ellis, Ph.D...... 53 Director(3)
Richard E. Engebrecht....... 69 Director(3)
William H. Gates, Sr........ 70 Director
Richard O. Martin, Ph.D..... 56 Director(2)
</TABLE>
- ---------------
(1) Member of Executive Committee.
(2) Member of Stock Option and Compensation Committee.
(3) Member of Audit Committee.
W. Robert Berg has been President, Chief Executive Officer and a Director
of the Company since 1988. Mr. Berg was the Company's Vice President, Operations
from 1985 to 1988. Mr. Berg has been involved in the management of
high-technology companies for the last 27 years. Mr. Berg also is a director of
the Washington State Biomedical and Biotechnology Association and the Washington
State Technology Alliance.
Edgar F. Rampy has been Vice President, Treasurer and Chief Financial
Officer of the Company since 1990. In 1990, Mr. Rampy served as Chief Financial
Officer of Quantum Medical Systems and assisted in its sale to Siemens
Corporation. From 1987 to 1989, Mr. Rampy was Chief Operating Officer of Carver
Corporation and, from 1979 to 1987, Chief Financial Officer of Data I/O
Corporation. He became a Certified Public Accountant in 1967.
Donald Rich has been Vice President, Operations of the Company since 1993.
From 1989 to 1993, Mr. Rich was employed by Interpoint Corporation, a
microelectronics manufacturer, serving as the Director of Quality Assurance from
1991 to 1993, and the Director of Operations from 1989 to 1991.
Thomas F. Mrowca has been Vice President, Sales and Marketing of the
Company since 1990. From 1976 to 1990, Mr. Mrowca was employed by Physio-Control
Corporation, where he held sales and marketing positions and was responsible for
research, new product development, new market development, product planning,
forecasting and pricing.
Marcia A. Page has been Vice President, Quality Assurance and Regulatory
Affairs of the Company since 1993. From 1989 to 1993, Ms. Page was the Company's
Manager of Quality Assurance. Ms. Page is the Past-President and Chairwoman and
current co-chair of the Organization of Regulatory and Clinical Associates and
is a member of the American Society of Quality Control and the Regulatory
Affairs Professionals Society.
S. Erik Hagstrom has been Vice President, Engineering of the Company since
1995. Mr. Hagstrom joined the Company in 1986 as a design engineer, was named a
Project Director in 1989 and a Senior Project Director in 1992. From 1984 to
1986, Mr. Hagstrom was an engineer at Biotronik Cardiac Pacing Systems.
R. Scott Asen has been a director of the Company since 1978 and its
Chairman of the Board since 1992. Since 1983, Mr. Asen has been President of
Asen & Co., Inc., an investment management firm. Mr. Asen has
36
<PAGE> 37
been a general partner of Pioneer IV, a venture capital investment fund and a
significant shareholder of the Company, since 1984. Mr. Asen also is a director
of Biomagnetic Technologies, Inc. and Davox Corporation.
Stephen J. Clearman has been a director of the Company since 1984. Since
1984, Mr. Clearman has been a principal of Geocapital Partners, a venture
capital fund that he cofounded and a significant shareholder of the Company, and
has formed three other venture capital partnerships. Mr. Clearman also is a
director of MemberWorks Inc., Expert Software, Inc. and World Access, Inc.
William D. Ellis, Ph.D. has been a director of the Company since 1981.
Since 1995, Dr. Ellis has been Chairman of the Board and Chief Executive Officer
of Personal Health Connections, Inc., an Internet-based health services company
that he cofounded. Dr. Ellis also is Chairman of PhyCom Corp., a managed health
care information services firm that he cofounded in 1988. From 1985 to 1988, Dr.
Ellis was the Company's President and Chief Executive Officer. Dr. Ellis is
Chairman of the Washington Software and Digital Media Alliance.
Richard E. Engebrecht has been a director of the Company since 1992. Since
1994, Mr. Engebrecht has been the Chairman of the Board of PrimeSource
Corporation (a successor to Momentum Corporation). From 1990 to 1994, Mr.
Engebrecht was Chairman of the Board and Chief Executive Officer of Momentum
Corporation, and, from 1986 to 1990, President and Chief Executive Officer of
VWR Corporation. Mr. Engebrecht also is a director of Penwest Ltd., VWR
Scientific Products Corporation and Prime Source Corporation.
William H. Gates, Sr. has been a director of the Company since January
1996. From 1983 to 1995, Mr. Gates was the Company's Secretary. Since 1964, Mr.
Gates has been a partner in the law firm Preston Gates & Ellis and its
predecessors, counsel to the Company. Mr. Gates also is a director of Mutual of
America Capital Management Corporation.
Richard O. Martin, Ph.D. has been a director of the Company since October
1995. Since 1991, Dr. Martin has been the President, Chief Executive Officer and
a director of Physio-Control Corporation. Dr. Martin also is a director of
Maxxim Medical, Inc. and Encore Orthopedic, Inc.
The Company's Board of Directors consists of seven directors. Directors are
elected at the annual meeting of shareholders to serve until they resign or are
removed, or are otherwise disqualified to serve, or until their successors are
elected and qualified. Messrs. Asen and Clearman were elected as directors
pursuant to an agreement among the original purchasers of Class A and Class B
Preferred Stock that terminates on the closing of this offering, which holders
of such shares include Mr. Asen and entities of which Mr. Asen or Mr. Clearman
are general partners or managing members, including Pioneer IV, Pioneer III-A
LLC, Pioneer III-B LLC and GeoCapital Ventures. Such purchasers agreed to vote
all their shares in favor of one director designated by Collier Enterprises (or
its transferee, Geocapital Corporation) and one director designated by Pioneer
III (or its transferee) for so long as the original purchasers hold shares of
such Preferred Stock. Messrs. Asen and Clearman will continue to serve as
directors after the closing of this offering.
Officers are elected annually and serve at the discretion of the Board of
Directors. The Company has not entered into employment agreements with any of
its executive officers. The Company intends to enter into indemnification
agreements with its directors and executive officers pursuant to which the
Company will agree to indemnify each director or executive officer against
certain liabilities arising by reason of such person's affiliation with the
Company.
DIRECTOR COMPENSATION
Directors of the Company currently receive no cash compensation. The Board
may consider alternative director compensation arrangements from time to time.
Each of Mr. Martin and Mr. Gates was granted an option to purchase 17,000
shares of Common Stock, with an exercise price of $2.50 per share, upon his
initial election to the Board, subject to the terms and conditions of the
Company's stock option plan, under which options vest over a four-year period.
SeaMED currently intends to grant options with similar terms to new outside
directors.
COMPENSATION COMMITTEE INTERLOCKS AND INSIDER PARTICIPATION
W. Robert Berg, the Company's President and Chief Executive Officer and a
director, served on the Stock Option and Compensation Committee during fiscal
year 1996.
37
<PAGE> 38
EXECUTIVE COMPENSATION
Summary Compensation
The following table sets forth certain information regarding the
compensation earned by the Company's Chief Executive Officer and the Company's
four other most highly compensated executive officers (the "Named Executive
Officers") for the fiscal year ended June 30, 1996.
SUMMARY COMPENSATION TABLE
<TABLE>
<CAPTION>
LONG-TERM
COMPENSATION AWARDS
-------------------
ANNUAL COMPENSATION SECURITIES
-------------------- UNDERLYING ALL OTHER
NAME AND PRINCIPAL POSITION SALARY($) BONUS($) OPTIONS/SARS(#)(1) COMPENSATION($)(2)
- --------------------------------------- --------- -------- ------------------- ------------------
<S> <C> <C> <C> <C>
W. Robert Berg......................... $ 175,000 $117,544 -- $2,731
President and Chief Executive Officer
Edgar F. Rampy......................... 108,000 36,271 8,867 1,692
Vice President, Treasurer
and Chief Financial Officer
Thomas F. Mrowca....................... 105,000 35,263 9,714 1,676
Vice President, Sales and Marketing
Donald Rich............................ 99,000 24,936 7,095 1,520
Vice President, Operations
S. Erik Hagstrom....................... 92,000 23,173 14,104 1,345
Vice President, Engineering
</TABLE>
- ---------------
(1) Represents options granted pursuant to the Company's stock option plans.
(2) Represents matching contributions under the Company's 401(k) plan.
Option Grants
The following table sets forth certain information regarding stock options
granted to the Named Executive Officers during the fiscal year ended June 30,
1996. No stock options were granted to Mr. Berg during fiscal year 1996.
OPTION GRANTS DURING FISCAL YEAR 1996
<TABLE>
<CAPTION>
POTENTIAL
REALIZABLE VALUE
AT
INDIVIDUAL GRANTS ASSUMED ANNUAL
- ---------------------------------------------------------------------------------- RATES OF STOCK
NUMBER OF PERCENT OF PRICE
SECURITIES TOTAL OPTIONS APPRECIATION FOR
UNDERLYING GRANTED TO EXERCISE OPTION TERM(2)
OPTIONS EMPLOYEES IN PRICE EXPIRATION -----------------
NAME GRANTED(#)(1) FISCAL YEAR ($/SH) DATE 5% ($) 10% ($)
- ----------------------------- ------------- ------------- --------- -------- ------- -------
<S> <C> <C> <C> <C> <C> <C>
Edgar F. Rampy............... 1,667 $2.50 10/25/05 $ 2,621 $ 6,642
7,200 6.7% 5.00 05/24/06 22,640 57,375
Thomas F. Mrowca............. 2,514 2.50 10/25/05 3,953 10,017
7,200 7.3% 5.00 05/24/06 22,640 57,375
Donald Rich.................. 2,295 2.50 10/25/05 3,608 9,144
4,800 5.3% 5.00 05/24/06 15,093 38,250
S. Erik Hagstrom............. 8,000 2.50 07/24/05 12,578 31,875
1,304 2.50 10/25/05 2,050 5,196
4,800 10.6% 5.00 05/24/06 15,093 38,250
</TABLE>
- ---------------
(1) Represents options granted pursuant to the Company's stock option plans. All
options were granted at fair market value at the date of grant. All options
vest 50% on the second anniversary of the date of grant, an additional 25%
on the third anniversary of the date of grant and an additional 25% on the
fourth anniversary of the date of grant.
(2) Represents amounts that may be realized upon exercise of the options
immediately prior to expiration of their terms assuming appreciation of 5%
and 10% over the option term. The 5% and 10% numbers are calculated based on
rules required by the Commission and do not reflect the Company's estimate
of future stock price growth. The actual value realized may be greater or
less than the potential realizable value set forth.
38
<PAGE> 39
Option Values
The following table sets forth certain information regarding the exercise
of stock options and unexercised stock options held as of June 30, 1996 by the
Named Executive Officers.
1996 FISCAL YEAR-END OPTION VALUES
<TABLE>
<CAPTION>
NUMBER OF
SECURITIES UNDERLYING VALUE OF UNEXERCISED
UNEXERCISED OPTIONS AT IN-THE-MONEY OPTIONS AT
SHARES FISCAL YEAR-END (#) FISCAL YEAR-END(1)
ACQUIRED ON VALUE --------------------------- ---------------------------
NAME EXERCISE(#) REALIZED EXERCISABLE UNEXERCISABLE EXERCISABLE UNEXERCISABLE
- ----------------------------------------- -------- ----------- ------------- ----------- -------------
<S> <C> <C> <C> <C> <C> <C>
W. Robert Berg................ 40,000 $ 93,600 65,503 60,000 $ 274,885 $37,500
Edgar F. Rampy................ 9,500 30,875 15,875 10,992 69,675 12,643
Thomas F. Mrowca.............. 7,000 22,750 12,875 11,839 56,175 14,760
Donald Rich................... -- -- 8,000 11,095 48,000 21,738
S. Erik Hagstrom.............. 8,985 17,370 3,989 15,933 17,031 30,565
</TABLE>
- ---------------
(1) Based on a fair market value of $5.00 per share as of June 30, 1996, as
determined by the Board of Directors.
STOCK PLANS
1988 Stock Option Plan
The SeaMED Corporation 1988 Stock Option Plan (the "1988 Plan") permits the
grant of options to purchase an aggregate of 680,000 shares of Common Stock to
regular full-time officers and key employees of the Company. The 1988 Plan is
administered by the Board of Directors, which generally has the authority to
select individuals who are to receive options and to specify the terms and
conditions of each option so granted, including the number of shares covered by
the option, the type of option (incentive or nonqualified), the exercise price
(which must be at least equal to the fair market value of the Common Stock on
the date of grant with respect to incentive stock options), the vesting
provisions and the option term. Unless otherwise provided by the Board of
Directors, any option granted under the 1988 Plan expires on the date set forth
in the optionee's option agreement or, if earlier, (i) the date specified in the
option agreement following an optionee's termination of service with the
Company, but not later than 12 months after such termination, other than
termination for cause, in which case the option terminates immediately, (ii) 12
months after the optionee's death or disability, or (iii) on various specified
dates in the event of a merger, consolidation, tender offer, takeover bid, sale
of assets or majority vote of the shareholders of the Company in favor of
dissolving, subject to reinstatement if such event does not occur.
As of September 30, 1996, options to purchase 293,383 shares of Common
Stock granted under the 1988 Plan had been exercised, options to purchase
385,179 shares were outstanding and 1,438 shares remained available for grant.
1995 Employee Stock Option and Incentive Plan
The purpose of the SeaMED Corporation 1995 Employee Stock Option and
Incentive Plan (the "1995 Plan") is to offer incentives and awards to those
employees, agents and consultants of the Company who are key to the Company's
growth, development and financial success, thereby aligning the personal
interests of such persons, through the ownership of Common Stock and other
incentives, with those of the Company's shareholders. The 1995 Plan combines the
features of an incentive and a nonqualified stock option plan, a stock award
plan and a stock appreciation rights ("SAR") plan. The 1995 Plan is a long-term
incentive compensation plan and is designed to provide a competitive and
balanced incentive and reward program for participants. A total of 200,000
shares of Common Stock is available under the 1995 Plan, of which, as of
September 30, 1996, options to purchase 105,020 shares had been granted and
options to purchase 94,980 shares were available for future grant; no options
have been exercised.
Terms of Stock Option Grants. The Compensation Committee has the authority
to select individuals who are to receive options under the 1995 Plan and to
specify the terms and conditions of each option so granted (incentive or
nonqualified), the exercise price (which must be at least equal to the fair
market value
39
<PAGE> 40
of the Common Stock on the date of grant with respect to incentive stock options
and options awarded to nonemployee directors), the vesting provisions and the
option term.
Stock Awards. The Compensation Committee is authorized under the 1995 Plan
to issue shares of Common Stock to eligible participants upon such terms and
conditions and subject to such limitations, if any (including, without
limitation, restrictions based upon the achievement of specific business
objectives, tenure, and other measures of individual or business performance),
and/or restrictions under applicable federal or state securities laws, and
conditions under which the same shall lapse, as the Compensation Committee may
determine. As of September 30, 1996, the Company had granted no such awards.
Stock Appreciation Rights. A SAR is an incentive award that permits the
holder to receive (per share covered thereby) the amount by which the fair
market value of a share of Common Stock on the date of exercise exceeds the fair
market value of such share on the date the SAR was granted. The Compensation
Committee may grant SARs independently or in tandem (such that the exercise of
the SAR or related stock option will result in forfeiture of the right to
exercise the related stock option or SAR for an equivalent number of shares)
with a stock option award. The Compensation Committee is authorized under the
1995 Plan to determine the times of exercise of granted SARs and their times of
expiration, which may not exceed 10 years. As of September 30, 1996, the Company
had granted no SARs.
1996 Employee Stock Purchase Plan
The Company has reserved an aggregate of 70,000 shares of Common Stock for
issuance under the SeaMED Corporation 1996 Employee Stock Purchase Plan (the
"ESPP"). The ESPP is intended to qualify under Section 423 of the Internal
Revenue Code of 1986, as amended, and permits eligible employees of the Company
(unless otherwise waived by the Board of the Directors, all employees who have
been employed by the Company for at least six months, except employees whose
customary employment is less than 20 hours per week and employees whose
customary employment is for not more than five months in any calendar year) to
purchase Common Stock through payroll deductions of up to 10% of their
compensation, provided that no employee may purchase Common Stock worth more
than $25,000 in any calendar year. The ESPP will be implemented with 10
consecutive six-month purchase periods, the first such purchase period to
commence upon the date that the Common Stock begins to trade on the Nasdaq Stock
Market and to end on June 30, 1997. Thereafter, purchase periods shall commence
on each subsequent January 1 and July 1. The price of Common Stock purchased
will be 85% of the lesser of the fair market value of the Common Stock on the
first day of the purchase period and the fair market value of the Common Stock
on the last day of the purchase period. The ESPP will expire on December 31,
2001. No shares have been issued under the ESPP.
40
<PAGE> 41
PRINCIPAL AND SELLING SHAREHOLDERS
The following table sets forth, as of September 30, 1996, certain
information regarding beneficial ownership of Common Stock and as adjusted to
reflect the sale of the Common Stock offered in this offering, by (i) each
person known by the Company to own beneficially 5% or more of the Common Stock;
(ii) each director of the Company; (iii) each Named Executive Officer; (iv) the
Selling Shareholders; and (v) all directors and executive officers as a group.
For purposes of this table, distributions of Common Stock by Geocapital Ventures
to certain of its limited partners who will be Selling Shareholders are deemed
to have occurred as of September 30, 1996. Unless otherwise indicated, all
persons listed have sole voting and investment power with respect to such
shares, subject to community property laws, where applicable.
<TABLE>
<CAPTION>
BENEFICIAL OWNERSHIP SHARES BENEFICIAL OWNERSHIP
PRIOR TO THE OFFERING TO BE AFTER THE OFFERING
----------------------- SOLD IN THE -----------------------
NAME AND ADDRESS SHARES(1) PERCENTAGE OFFERING SHARES PERCENTAGE
- -------------------------------------- --------- ---------- ----------- --------- ----------
<S> <C> <C> <C> <C> <C>
Geocapital Ventures(2)................ 488,771 13.6% -- 488,771 9.5%
James G. Niven(3)..................... 420,550 11.7% 50,000 370,550 7.2%
Pioneer IV(4)......................... 379,763 10.5% -- 379,763 7.4%
Pioneer III-B LLC(4).................. 253,069 7.0% -- 253,069 4.9%
Pioneer III-A LLC(4).................. 199,709 5.5% -- 199,709 3.9%
R. Scott Asen(4)(5)................... 1,328,695 36.8% -- 1,328,695 25.9%
Stephen J. Clearman(2)(6)............. 488,771 13.6% -- 488,771 9.5%
William D. Ellis, Ph.D.(7)............ 121,421 3.4% 10,000 111,421 2.2%
Richard E. Engebrecht(7).............. 27,667 * -- 27,667 *
William H. Gates, Sr.................. 28,000 * -- 28,000 *
Richard O. Martin, Ph.D............... -- -- -- -- --
W. Robert Berg(7)(8).................. 193,503 5.3% -- 193,503 3.7%
Edgar F. Rampy(7)(9).................. 38,375 1.1% -- 38,375 *
Donald Rich(7)(10).................... 12,000 * -- 12,000 *
Thomas F. Mrowca(7)(11)............... 38,375 1.1% -- 38,375 *
S. Erik Hagstrom(7)(12)............... 18,596 * -- 18,596 *
Allen & Company Incorporated(13)...... 105,732 2.9% 33,333 72,399 1.4%
Terry Allen Kramer.................... 66,666 1.8% 33,333 33,333 *
Brae Group, Inc....................... 66,666 1.8% 25,000 41,666 *
Robert M. Arnold...................... 49,600 1.4% 12,400 37,200 *
Dorothy Mae Kennedy................... 40,000 1.1% 20,000 20,000 *
The Equitable Life Assurance Society 38,535 1.1% 38,535 -- --
of the United States................
Gary Altman(14)....................... 36,676 1.0% 3,000 33,676 *
IBM Retirement Plan Trust............. 27,788 * 27,788 -- --
Pantaleoni Associates................. 17,367 * 17,367 -- --
Equitable Variable Life Insurance 15,358 * 15,358 -- --
Company.............................
Thomas M. Podl........................ 10,000 * 5,000 5,000 *
John W. Poduska....................... 8,342 * 8,342 -- --
S. B. Enterprises..................... 6,734 * 734 6,000 *
J.K. Jamieson......................... 4,166 * 4,166 -- --
</TABLE>
41
<PAGE> 42
<TABLE>
<CAPTION>
BENEFICIAL OWNERSHIP SHARES BENEFICIAL OWNERSHIP
PRIOR TO THE OFFERING TO BE AFTER THE OFFERING
----------------------- SOLD IN THE ----------------------
NAME AND ADDRESS SHARES(1) PERCENTAGE OFFERING SHARES PERCENTAGE
- -------------------------------------- --------- ---- ------ ------- ----------
<S> <C> <C> <C> <C> <C>
Robert M. Bridgforth, Jr.............. 3,689 * 3,689 -- --
Lee Paul Klingenstein................. 2,781 * 2,781 -- --
Jerry R. Pyle......................... 2,781 * 2,781 -- --
Peter Strauss......................... 2,781 * 2,781 -- --
John P. Rosenthal..................... 1,385 * 1,385 -- --
Irwin W. Silverberg................... 1,385 * 1,385 -- --
Allen Puckett......................... 800 * 800 -- --
Peter Anastos......................... 322 * 322 -- --
All directors and executive officers
as a group (12 persons)(7)(15)...... 2,310,342 61.9% 10,000 2,300,342 43.7%
</TABLE>
- ---------------
* Less than 1%.
(1) Computed in accordance with Rule 13d-3(d)(1) of the Securities Exchange Act
of 1934, as amended.
(2) The address of Mr. Clearman and Geocapital Ventures is One Bridge Plaza,
Fort Lee, NJ 07024. Includes shares to be distributed to its limited
partners immediately prior to the closing of this offering.
(3) The address of Mr. Niven is c/o Sotheby's, 1334 York Avenue, New York, NY
10021.
(4) The address of Mr. Asen, Pioneer IV, Pioneer III-B LLC and Pioneer III-A
LLC is c/o Asen and Co., Inc., 224 East 49th Street, New York, NY 10017.
(5) Includes 5,000 shares of Common Stock held in an IRA and 199,709, 253,069
shares and 379,763 shares beneficially owned through Pioneer III-A LLC,
Pioneer III-B LLC and Pioneer IV (collectively, the "Pioneer Entities"),
respectively, of which Mr. Asen is either a managing member or a general
partner. Although Mr. Asen has full authority to vote and direct the
disposal of shares owned by the Pioneer Entities, he disclaims beneficial
ownership of shares held by such investment partnerships to the extent
partnership interests in such partnerships are held by other persons.
(6) Represents 405,037 shares beneficially owned through Geocapital Ventures,
of which Mr. Clearman is a general partner. Includes shares to be
distributed to its limited partners immediately prior to the closing of
this offering.
(7) May include stock jointly or separately owned with spouse.
(8) Includes 65,503 shares of Common Stock issuable upon exercise of options
that are currently exercisable or will become exercisable within 60 days of
September 30, 1996.
(9) Includes 16,375 shares of Common Stock issuable upon exercise of options
that are currently exercisable or will become exercisable within 60 days of
September 30, 1996.
(10) Represents 12,000 shares of Common Stock issuable upon exercise of options
that are currently exercisable or will become exercisable within 60 days of
September 30, 1996.
(11) Includes 13,375 shares of Common Stock issuable upon exercise of options
that are currently exercisable or will become exercisable within 60 days of
September 30, 1996.
(12) Includes 4,403 shares of Common Stock issuable upon exercise of options
that are currently exercisable or will become exercisable within 60 days of
September 30, 1996.
(13) Allen & Company Incorporated acted as placement agent with respect to the
sale of Class D Preferred Stock. Includes 39,066 shares of Common Stock
issuable upon exercise of a warrant that is currently exercisable.
(14) Mr. Altman is an employee of the Company. Includes 12,478 shares of Common
Stock issuable upon exercise of options that are currently exercisable or
will become exercisable within 60 days of September 30, 1996.
(15) Includes 122,023 shares of Common Stock issuable upon exercise of options
that are currently exercisable or will become exercisable within 60 days of
September 30, 1996.
42
<PAGE> 43
CERTAIN TRANSACTIONS
In January 1995, the Company issued shares of Class D Preferred Stock
convertible into an aggregate of 390,666 shares of Common Stock at the ratio of
3.75 shares of Class D Preferred Stock for each share of Common Stock. Dr. Ellis
and Mr. Engebrecht, directors of the Company, purchased 25,000 and 40,000
shares, respectively, of Class D Preferred Stock, which shares are convertible
into 6,667 and 10,667 shares of Common Stock, respectively. The Company sold
such securities pursuant to a preferred stock purchase agreement on the same
terms as were sold to nonaffiliated purchasers. The terms of the Class D
Preferred Stock provides that all such shares shall be converted into Common
Stock upon the consummation of this offering.
On October 11, 1995, W. Robert Berg, the Company's Chief Executive Officer
and President, received a $75,000 loan from the Company, the proceeds of which
he used to purchase 30,000 shares of Common Stock. The loan is evidenced by an
unsecured promissory note that bears interest at the floating minimum statutory
rate of interest set by the Internal Revenue Service from time to time. Mr. Berg
may prepay principal and interest at any time without penalty; unpaid principal
and interest are due on October 11, 2000. As of September 30, 1996, aggregate
principal and accrued interest on this loan were approximately $80,000.
William H. Gates, Sr., a director of the Company, is also a partner in the
law firm Preston Gates & Ellis, the Company's counsel.
Physio-Control Corporation, a company of which Richard O. Martin, a
director of the Company, serves as President and Chief Executive Officer and a
director, has retained the Company to provide engineering and manufacturing
services. The Company recognized revenues with respect to such services of
approximately $1.0 million in fiscal year 1995 and $355,000 in fiscal year 1996.
The Company recognized no revenues in fiscal year 1994 with respect to such
services.
DESCRIPTION OF CAPITAL STOCK
The authorized capital stock of the Company consists of 10,000,000 shares
of Common Stock, no par value, 1,500,000 shares of Class A Preferred Stock, no
par value, 450,000 shares of Class B Preferred Stock, no par value, 5,100,000
shares of Class C Preferred Stock, no par value, 2,000,000 shares of Class D
Preferred Stock, no par value, and 5,000,000 shares of Undesignated Preferred
Stock. The following summary description of the Company's capital stock is
qualified in its entirety by reference to the Articles of Incorporation and the
Bylaws of the Company, copies of which are filed as exhibits to the Registration
Statement of which this Prospectus forms a part.
COMMON STOCK
As of September 30, 1996, there were 673,157 shares of Common Stock
outstanding. Holders of Common Stock are entitled to one vote per share on all
matters submitted to a vote of shareholders, and have no cumulative voting
rights and no preemptive, subscription or sinking fund rights. Subject to
preferences that may be applicable to any then-outstanding Preferred Stock,
holders of Common Stock will be entitled to receive ratably such dividends as
may be declared by the Board of Directors out of funds legally available
therefor. See "Dividend Policy." In the event of a liquidation, dissolution or
winding up of the Company, holders of Common Stock will be entitled to share
ratably in all assets remaining after payment of liabilities and the liquidation
preference to any then-outstanding Preferred Stock.
PREFERRED STOCK
As of September 30, 1996, there were outstanding 1,458,500, 450,000,
5,082,704, and 1,465,000 shares of Class A, B, C and D Preferred Stock,
respectively. The designations of rights and preferences with respect to the
Preferred Stock generally provides for liquidation, conversion, redemption,
voting and other rights. Holders of Class A and D Preferred Stock are entitled
to cumulative annual dividends of $0.10 and $0.08, respectively. All shares of
outstanding Preferred Stock will be converted automatically into an aggregate of
2,934,029 shares of Common Stock upon the closing of this offering. Upon such
closing, holders of Class A
43
<PAGE> 44
and D Preferred Stock are entitled to all cumulative dividends to the time of
such conversion, which were approximately $1.7 million as of September 30, 1996.
Pursuant to SeaMED's Articles of Incorporation, the Board of Directors is
authorized to issue 5,000,000 shares of the Undesignated Preferred Stock in one
or more classes or series, or both, and, without further approval of the
shareholders, to fix dividend rights and terms, conversion rights, voting
rights, redemption rights and terms, liquidation preferences and any other
rights, preferences, privileges and restrictions applicable to each class or
series of Undesignated Preferred Stock. The issuance of Undesignated Preferred
Stock, while providing flexibility in connection with possible acquisitions and
other corporate purposes, could, among other things, adversely affect the voting
power of the holders of Common Stock and, under certain circumstances, make it
more difficult for a third party to gain control of the Company, discourage bids
for Common Stock at a premium or otherwise adversely affect the market price of
the Common Stock. The Company has no current plans to issue any Undesignated
Preferred Stock.
WARRANT
The investment banking firm of Allen & Company Incorporated acted as
placement agent with respect to the sale of Class D Preferred Stock. As partial
compensation for such services, it received, and beneficially owns, a warrant to
purchase 39,066 shares of Common Stock at a price of $4.70 per share.
REGISTRATION RIGHTS
Pursuant to certain agreements between the Company and certain purchasers
of capital stock (collectively, the "Holders"), who will hold approximately
2,555,637 shares of Common Stock (the "Registerable Securities") following this
offering, the Holders are entitled to certain rights with respect to
registration of such shares under the Securities Act. The Holders include R.
Scott Asen, each of the Pioneer Entities and Geocapital Ventures. If the Company
proposes to register any of its securities, with certain exceptions that include
a registration relating solely to employee benefit plans, either for its own
account or the account of other security holders, the Company is required to
notify the Holders and to use its best efforts to effect the registration, and
the Holders are entitled to include at the Company's expense their Registerable
Securities in such registration, subject to certain conditions and limitations.
In addition, at any time after the first anniversary of the closing of this
offering, the Holders may require the Company to file a registration statement
under the Securities Act at the Company's expense, and the Company is required
to use its best efforts to effect such registration, subject to certain
conditions and limitations. The Holders other than the Selling Shareholders have
waived their rights to have any of their shares of Common Stock registered in
this offering.
CERTAIN PROVISIONS OF ARTICLES OF INCORPORATION AND BYLAWS
Shareholder Action by Written Consent; Special Meetings of Shareholders
The Company's Bylaws permit any action required or permitted to be taken by
the Company's shareholders to be effected at a duly called annual or special
meeting of shareholders or by unanimous consent in writing. Additionally, the
Articles of Incorporation and Bylaws require that special meetings of the
shareholders of the Company may be called only by a majority of the Board of
Directors or an authorized committee thereof.
Advance Notice Requirements for Shareholder Proposals and Director
Nominations
The Company's Bylaws provide that shareholders seeking to bring business
before or to nominate directors at any meeting of shareholders must provide
timely notice thereof in writing. To be timely, a shareholder's notice must be
delivered to, or mailed and received at, the principal executive offices of the
Company not less than (i) with respect to an annual meeting, 120 calendar days
in advance of the one-year anniversary of the date that the Company's proxy
statement was released to shareholders in connection with the previous year's
annual meeting, except that if no annual meeting was held in the previous year
or if the date of the annual meeting has been changed by more than 30 calendar
days from the date contemplated at
44
<PAGE> 45
the time of the previous year's proxy statement, such notice must be received by
the Company a reasonable time before the Company's proxy statement is to be
released and (ii) with respect to a special meeting of shareholders, a
reasonable time before the Company's proxy statement is to be released. The
Bylaws also specify certain requirements for a shareholder's notice to be in
proper written form. These provisions may preclude some shareholders from
bringing matters before the shareholders or from making nominations for
directors.
Director and Officer Indemnification
The Washington Business Act provides that a Washington corporation may
include provisions in its articles of incorporation relieving each of its
directors of monetary liability arising out of his or her conduct as a director
for breach of his or her fiduciary duty, except liability for (i) acts or
omissions of a director finally adjudged to be intentional misconduct or a
knowing violation of law, (ii) conduct in violation of Section 23B.08.310 of the
Washington Business Act (which section relates to unlawful distributions), or
(iii) any transaction with respect to which it is finally adjudged that a
director personally received benefit in money, property or services to which the
director was not legally entitled. The Company's Articles of Incorporation
include such provisions.
The Company's Articles of Incorporation and Bylaws provide that the Company
shall, to the fullest extent permitted by law, indemnify and advance expenses to
each of its currently acting and former directors and officers, and may so
indemnify and advance expenses to each of its current and former employees and
agents. The Company believes that the foregoing provisions are necessary to
attract and retain qualified persons as directors and officers. Prior to
consummation of this offering, the Company intends to enter into separate
indemnification agreements with each of its directors and executive officers in
order to effectuate such provisions.
PROVISIONS AFFECTING ACQUISITIONS AND BUSINESS COMBINATIONS
The Washington Business Act contains certain provisions that may have the
effect of delaying or discouraging a hostile takeover of the Company. Chapter
23B.19 of the Washington Business Act prohibits a target corporation, with
certain exceptions, from engaging in certain significant business transactions
(such as a merger or sale of assets) with a person or group of persons which
beneficially acquires 10% or more of the corporation's voting securities (an
"Acquiring Entity") for a period of five years after such acquisition, unless
the transaction is approved by a majority of the members of the target
corporation's board of directors prior to the date of the transaction. An
Acquiring Entity is further prohibited from engaging in significant business
transactions with the target corporation unless the per share consideration paid
to holders of outstanding shares of common stock and other classes of stock of
the target corporation meet certain minimum criteria. These provisions may have
the effect of delaying, deterring or preventing a change in control of the
Company.
TRANSFER AGENT AND REGISTRAR
The transfer agent and registrar for the Common Stock is ChaseMellon
Shareholder Services.
45
<PAGE> 46
SHARES ELIGIBLE FOR FUTURE SALE
Upon completion of this offering, the Company will have 5,136,906 shares of
Common Stock outstanding, assuming the issuance of 1,529,720 shares by the
Company hereby (5,414,406 shares if the Underwriters' over-allotment option is
exercised in full). Of the outstanding shares, 1,850,000 (2,127,500 if the
Underwriters' over-allotment option is exercised in full) will be freely
tradable without restriction or further registration under the Securities Act,
unless held by "affiliates" of the Company, as that term is defined in Rule 144
under the Securities Act.
The remaining 3,286,906 shares of Common Stock are "restricted securities"
within the meaning of Rule 144 under the Securities Act and were issued and sold
by the Company in private transactions and may be publicly sold only if
registered under the Securities Act or sold in accordance with an applicable
exemption from registration, such as Rule 144. Of these restricted securities,
63,609 shares are not subject to lockup agreements and will be eligible for sale
following this offering in the public market as follows: 56,051 shares will be
eligible for sale immediately without restriction pursuant to Rule 144(k) and
7,558 shares will be eligible for sale 90 days after the date of this offering
under Rule 701 and in reliance on Rule 144 without having to comply with certain
restrictions of Rule 144 as described below. The Company, its officers and
directors, the Selling Shareholders and certain other shareholders (representing
3,223,297 shares of restricted securities) have agreed pursuant to lockup
agreements that they will not sell, directly or indirectly, any Common Stock
without the prior consent of Piper Jaffray Inc. for a period of 180 days after
the closing of this offering. Upon the expiration of this 180-day period (or
earlier upon the consent of Piper Jaffray Inc.), 2,900,964 of these restricted
shares will become eligible for sale in the public market as follows: 2,713,724
shares will be eligible for immediate sale without restriction pursuant to Rule
144(k) and 187,240 shares will be eligible for sale immediately (or 90 days
after the date of this offering with the earlier consent of Piper Jaffray Inc.)
under Rule 701 and in reliance on Rule 144 without having to comply with certain
restrictions of Rule 144 as described below.
In general, under Rule 144, as currently in effect, a person who has owned
shares for at least two years would be entitled to sell, within any three-month
period, that number of shares that does not exceed the greater of (i) 1% of the
then-outstanding shares of Common Stock (approximately 51,369 shares immediately
after this offering) and (ii) the average weekly trading volume in the Common
Stock during the four calendar weeks preceding the date the notice of sale is
filed with the Commission, subject to certain other limitations and
restrictions. In addition, a person who is not deemed to have been an affiliate
of the Company at any time during the three months preceding a sale, and who has
beneficially owned the shares proposed to be sold for at least three years,
would be entitled to sell such shares under Rule 144(k) without regard to the
requirements described above. Under Rule 701, persons who purchase shares upon
exercise of options granted prior to the effective date of this offering are
entitled to sell such shares 90 days after the effective date of this offering
and in reliance on Rule 144 without having to comply with the holding period
requirements of Rule 144 and, in the case of nonaffiliates, without having to
comply with the public information, volume limitation, or notice provisions of
Rule 144.
The holders of options to purchase 154,700 shares which have vested and are
not subject to lockup agreements could exercise their options and sell these
shares in compliance with Rule 701 beginning 90 days after the effective date of
this offering. The Company intends to file registration statements under the
Securities Act covering an aggregate of approximately 656,617 shares of Common
Stock reserved for issuance under the 1988 Plan, the 1995 Plan and the ESPP.
Such registration statements are expected to be filed 180 days after the date of
this Prospectus and will automatically become effective upon filing.
Accordingly, shares registered under such registration statements will be
available for sale in the open market, unless such shares are subject to vesting
restrictions with the Company or the contractual restrictions described above.
In addition, certain shareholders, representing approximately 2,727,104 shares
of Common Stock, have the right, subject to certain conditions, to include their
shares in future registration statements relating to SeaMED's securities and to
cause SeaMED to register certain shares of Common Stock owned by them.
The Company can make no prediction as to the effect, if any, that sales of
shares of Common Stock or the availability of shares of Common Stock for sale
will have on the market price prevailing from time to time. Nevertheless, sales
of substantial amounts of Common Stock in the public markets or the perception
that such sales could occur could adversely affect the market price of the
Common Stock or the Company's ability to raise capital through an offering of
its equity securities.
46
<PAGE> 47
UNDERWRITING
The Company and the Selling Shareholders have entered into a Purchase
Agreement (the "Purchase Agreement") with the underwriters listed in the table
below (the "Underwriters"), for whom Piper Jaffray Inc. and Needham & Company,
Inc. are acting as representatives (the "Representatives"). Subject to the terms
and conditions set forth in the Purchase Agreement, the Company and the Selling
Shareholders have agreed to sell to the Underwriters, and each of the
Underwriters has severally agreed to purchase, the following number of shares of
Common Stock set forth opposite each Underwriter's name in the table below:
<TABLE>
<CAPTION>
NUMBER OF
NAME SHARES
-------------------------------------------------------------------------- ----------
<S> <C>
Piper Jaffray Inc......................................................... 595,000
Needham & Company, Inc.................................................... 595,000
Bear, Stearns & Co. Inc. ................................................. 60,000
Alex. Brown & Sons Incorporated........................................... 60,000
Hambrecht & Quist LLC..................................................... 60,000
Lehman Brothers Inc....................................................... 60,000
Montgomery Securities..................................................... 60,000
Robertson, Stephens & Company, LLC........................................ 60,000
Smith Barney Inc.......................................................... 60,000
UBS Securities LLC........................................................ 60,000
Cowen & Company........................................................... 30,000
Pacific Crest Securities.................................................. 30,000
Ragen Mackenzie Incorporated.............................................. 30,000
Raymond James & Associates, Inc. ......................................... 30,000
The Robinson-Humphrey Company, Inc........................................ 30,000
Volpe, Welty & Company.................................................... 30,000
---------
Total........................................................... 1,850,000
=========
</TABLE>
Subject to the terms and conditions of the Purchase Agreement, the
Underwriters have agreed to purchase all of the Common Stock being sold pursuant
to the Purchase Agreement, if any is purchased (excluding shares covered by the
over-allotment option granted therein). In the event of a default by any
Underwriter, the Purchase Agreement provides that, in certain circumstances,
purchase commitments of the nondefaulting Underwriters may be increased or the
Purchase Agreement may be terminated.
The Representatives have advised the Company and the Selling Shareholders
that the Underwriters propose to offer the shares of Common Stock directly to
the public initially at the public offering price set forth on the cover page of
this Prospectus and to certain dealers at such price less a concession of not
more than $0.42 per share. Additionally, the Underwriters may allow, and such
dealers may reallow, a concession not in excess of $0.10 per share to certain
other dealers. After the initial public offering, the public offering price and
other selling terms may be changed by the Underwriters.
The Company has granted to the Underwriters an option, exercisable by the
Representatives within 30 days after the date of the Purchase Agreement, to
purchase up to an additional 277,500 shares of Common Stock at the same price
per share to be paid by the Underwriters for the other shares offered hereby. If
the Underwriters purchase any of such additional shares pursuant to this option,
each Underwriter will be committed to purchase such additional shares in
approximately the same proportion as set forth in the table above. The
Underwriters may exercise the option only for the purpose of covering
over-allotments, if any, made in connection with the distribution of the Common
Stock offered hereby.
The Representatives have informed the Company and the Selling Shareholders
that neither they, nor any other member of the National Association of
Securities Dealers, Inc. participating in the distribution of this offering,
will make sales of the Common Stock offered hereby to accounts over which they
exercise discretionary authority without the prior specific written approval of
the customer.
47
<PAGE> 48
As of the date of this Prospectus, Needham Capital SBIC, L.P., an affiliate
of Needham & Company, Inc., beneficially owned shares of Class D Preferred Stock
convertible into 133,333 shares of Common Stock. These shares were purchased on
January 3, 1995 in reliance upon the exemption from registration set forth in
Section 4(2) of the Securities Act relating to sales by an issuer not involving
any public offering. Needham & Company, Inc. and certain of its affiliates may
be deemed to own shares convertible into 35,555 shares of Common Stock held by
Needham Capital SBIC, L.P. as a result of ownership interests in such
partnership.
The offering of the shares is made for delivery when, as and if accepted by
the Underwriters and subject to prior sale and to withdrawal, cancellation or
modification of this offering without notice. The Underwriters reserve the right
to reject an order for the purchase of shares in whole or in part.
The officers and directors of the Company, the Selling Shareholders and
certain other shareholders designated by the Representatives, who will
beneficially own in the aggregate 3,223,297 shares of Common Stock after this
offering, have agreed that they will not, directly or indirectly, sell, contract
to sell, make any short sale, pledge or otherwise dispose of any shares of
Common Stock, options to acquire shares of Common Stock or securities
exchangeable for or convertible into shares of Common Stock that such persons
may own, of record or beneficially, or have the right to acquire, for a period
of 180 days after the closing of this offering, without the prior written
consent of Piper Jaffray Inc. The Company has agreed that it will not, directly
or indirectly, without the prior written consent of Piper Jaffray Inc., issue,
offer, sell, contract to sell, pledge or otherwise dispose of any shares of
Common Stock, options or warrants to acquire shares of Common Stock or
securities exchangeable for or convertible into Common Stock during the 180-day
period following the closing of this offering, except that the Company may issue
shares upon the exercise of options granted prior to the date hereof, and may
grant additional options under the Company's existing stock option and purchase
plans.
Prior to this offering, there has been no public market for the Common
Stock. The initial public offering price for the Common Stock was determined by
negotiations between the Company and the Representatives. Among the factors
considered in determining the initial public offering price were prevailing
market and economic conditions, the Company's revenues and earnings, estimates
of the Company's business potential and prospects, the present state of the
Company's business operations, an assessment of the Company's management and the
consideration of the above factors in relation to the market valuations of
companies in related businesses. The initial public offering price for the
Common Stock should not be considered as an indication of the actual value of
the Common Stock offered hereby. In addition, there can be no assurance that the
Common Stock may be resold at a price equal to or greater than the initial
public offering price. See "Risk Factors -- Absence of Prior Market; Potential
Volatility of Common Stock Price."
The Company and the Selling Shareholders have agreed to indemnify the
Underwriters and their controlling persons against certain liabilities,
including liabilities under the Securities Act, and to contribute to payments
the Underwriters may be required to make in respect thereof.
LEGAL MATTERS
The validity of the shares of Common Stock offered hereby will be passed
upon for the Company and the Selling Shareholders by Preston Gates & Ellis,
Seattle, Washington. William H. Gates, Sr., a partner of the firm and a director
of the Company, beneficially owns 28,000 shares of Common Stock. Mark R. Beatty,
a partner of the firm, serves as Secretary of the Company. Certain legal matters
will be passed upon for the Underwriters by Perkins Coie, Seattle, Washington.
EXPERTS
The financial statements and schedule of the Company as of June 30, 1995
and 1996, and for each of the three years in the period ended June 30, 1996,
appearing in this Prospectus and elsewhere in the Registration Statement have
been audited by Ernst & Young LLP, independent auditors, as set forth in their
reports thereon appearing elsewhere herein, and are included in reliance upon
such reports given upon the authority of such firm as experts in accounting and
auditing.
48
<PAGE> 49
ADDITIONAL INFORMATION
The Company has filed with the Commission a Registration Statement on Form
S-1 under the Securities Act with respect to the shares of Common Stock offered
hereby (the "Registration Statement"). This Prospectus, which constitutes part
of the Registration Statement, does not contain all of the information set forth
in the Registration Statement and the exhibits and schedule thereto, certain
portions of which have been omitted as permitted by the rules and regulations of
the Commission. For further information with respect to the Company and the
Common Stock, reference is made to the Registration Statement, including the
exhibits and schedule thereto. Statements contained in this Prospectus as to the
contents of any contract, agreement or any other document referred to herein are
not necessarily complete and in each instance reference is made to the copy of
such contract, agreement or other document for a more complete description of
the matters involved, and each such statement shall be deemed qualified in its
entirety by such reference. The Registration Statement, including the exhibits
and schedule thereto, may be inspected without charge at the Commission's
principal office at 450 Fifth Street, N.W., Washington, D.C. 20549, the New York
Regional Office located at 7 World Trade Center, Suite 1300, New York, New York
10048, and the Chicago Regional Office located at Citicorp Center, 500 West
Madison Street, Suite 1400, Chicago, Illinois 60661, or obtained upon payment of
prescribed rates from the Public Reference Section of the Commission at its
principal office in Washington, D.C. The Commission maintains a web site on the
Internet at http://www.sec.gov that contains reports, proxy and information
statements and other information regarding registrants that file electronically
with the Commission.
The Company intends to furnish its shareholders with annual reports
containing financial statements audited by its independent auditors and
quarterly reports containing unaudited financial information for the first three
quarters of each fiscal year.
49
<PAGE> 50
(This Page Intentionally Left Blank)
<PAGE> 51
SEAMED CORPORATION
INDEX TO FINANCIAL STATEMENTS
<TABLE>
<S> <C>
Report of Ernst & Young LLP, Independent Auditors..................................... F-2
Financial Statements:
Balance Sheets as of June 30, 1995 and 1996 and September 30, 1996.................. F-3
Statements of Income for the Years Ended June 30, 1994, 1995 and 1996 and the
Quarters Ended September 30, 1995 and 1996....................................... F-4
Statements of Shareholders' Equity for the Years Ended June 30, 1994, 1995 and 1996
and the Quarter Ended September 30, 1996......................................... F-5
Statements of Cash Flows for the Years Ended June 30, 1994, 1995 and 1996 and the
Quarters Ended September 30, 1995 and 1996....................................... F-6
Notes to Financial Statements....................................................... F-7
</TABLE>
F-1
<PAGE> 52
REPORT OF ERNST & YOUNG LLP, INDEPENDENT AUDITORS
Board of Directors
SeaMED Corporation
We have audited the accompanying balance sheets of SeaMED Corporation as of
June 30, 1995 and 1996, and the related statements of income, shareholders'
equity, and cash flows for each of the three years in the period ended June 30,
1996. These financial statements are the responsibility of the Company's
management. Our responsibility is to express an opinion on these financial
statements based on our audits.
We conducted our audits in accordance with generally accepted auditing
standards. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material
misstatements. An audit includes examining, on a test basis, evidence supporting
the amounts and disclosures in the financial statements. An audit also includes
assessing the accounting principles used and significant estimates made by
management, as well as evaluating the overall financial statement presentation.
We believe that our audits provide a reasonable basis for our opinion.
In our opinion, the financial statements referred to above present fairly,
in all material respects, the financial position of SeaMED Corporation as of
June 30, 1995 and 1996, and the results of its operations and its cash flows for
each of the three years in the period ended June 30, 1996, in conformity with
generally accepted accounting principles.
Seattle, Washington
August 6, 1996 ERNST & YOUNG LLP
F-2
<PAGE> 53
SEAMED CORPORATION
BALANCE SHEETS
ASSETS
<TABLE>
<CAPTION>
PRO FORMA AT
JUNE 30, SEPTEMBER 30,
-------------------------- SEPTEMBER 30, 1996
1995 1996 1996 (NOTE 6)
---------- ----------- ----------- ------------
(UNAUDITED) (UNAUDITED)
<S> <C> <C> <C> <C>
Current assets:
Cash................................. $ 70,383 $ 2,912 $ 3,512 $ 3,512
Short-term investments............... 200,000 -- -- --
Accounts receivable, net of allowance
of $204,483 in 1995; $252,226 in
1996; and $277,563 at September
30, 1996.......................... 3,354,542 5,875,933 5,546,874 5,546,874
Inventories.......................... 3,719,656 6,697,248 7,224,443 7,224,443
Deferred income taxes................ 529,682 625,221 625,221 625,221
Prepaid expenses..................... 60,148 63,536 80,073 80,073
---------- ----------- ----------- -----------
Total current assets................... 7,934,411 13,264,850 13,480,123 13,480,123
Fixed assets........................... 1,856,996 2,655,265 2,725,648 2,725,648
Deposits and other assets.............. 108,964 144,220 331,966 331,966
---------- ----------- ----------- -----------
Total assets........................... $9,900,371 $16,064,335 $16,537,737 $ 16,537,737
========== =========== =========== ===========
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Notes payable to bank................ $ 555,000 $ 1,817,000 $ 2,245,755 $ 2,245,755
Accounts payable..................... 1,185,539 2,688,160 2,350,205 2,350,205
Accrued expenses and reserves........ 1,401,042 3,301,064 2,823,716 4,553,502
Current portion of long-term debt.... 296,067 461,990 583,432 583,432
---------- ----------- ----------- -----------
Total current liabilities.............. 3,437,648 8,268,214 8,003,108 9,732,894
Long-term debt, less current portion... 1,221,106 1,285,782 1,535,236 1,535,236
Commitments
Convertible redeemable preferred stock,
issued and outstanding shares of all
classes -- 8,456,204 in 1995 and 1996
and at September 30, 1996; none pro
forma (liquidation
value -- $6,308,200)................. 5,279,514 5,279,514 5,279,514 --
Shareholders' equity (deficit):
Preferred stock, no par value:
Authorized shares -- 14,050,000,
of which 9,050,000 have been
designated convertible
redeemable shares............... -- -- -- --
Common stock, no par value:
Authorized shares -- 10,000,000;
issued and outstanding shares --
548,964 in 1995; 668,707 in
1996; 673,157 at September 30,
1996; 3,607,186 pro forma....... 783,560 886,828 889,298 5,344,607
Note receivable from officer......... -- (75,000) (75,000) (75,000)
Retained earnings (deficit).......... (821,457) 418,997 905,581 --
---------- ----------- ----------- -----------
Total shareholders' equity (deficit)... (37,897) 1,230,825 1,719,879 5,269,607
---------- ----------- ----------- -----------
Total liabilities and shareholders'
equity............................... $9,900,371 $16,064,335 $16,537,737 $ 16,537,737
========== =========== =========== ===========
</TABLE>
See accompanying notes.
F-3
<PAGE> 54
SEAMED CORPORATION
STATEMENTS OF INCOME
<TABLE>
<CAPTION>
QUARTER ENDED
YEAR ENDED JUNE 30, SEPTEMBER 30,
------------------------------------------- --------------------------
1994 1995 1996 1995 1996
----------- ----------- ----------- ---------- -----------
(UNAUDITED)
<S> <C> <C> <C> <C> <C>
Revenues:
Manufacturing.......... $10,029,188 $11,940,610 $17,724,883 $3,475,211 $ 6,723,718
Engineering............ 4,690,876 5,720,600 8,405,352 1,524,797 3,352,451
----------- ----------- ----------- ---------- -----------
14,720,064 17,661,210 26,130,235 5,000,008 10,076,169
Costs of revenues:
Manufacturing.......... 7,537,768 9,330,095 13,541,280 2,729,566 5,438,767
Engineering............ 4,426,852 5,260,489 7,551,399 1,477,687 2,952,746
----------- ----------- ----------- ---------- -----------
11,964,620 14,590,584 21,092,679 4,207,253 8,391,513
----------- ----------- ----------- ---------- -----------
Gross margin............. 2,755,444 3,070,626 5,037,556 792,755 1,684,656
Marketing, general and
administrative
expenses............... 1,818,177 1,930,734 2,937,556 490,898 846,670
----------- ----------- ----------- ---------- -----------
Operating income......... 937,267 1,139,892 2,100,000 301,857 837,986
Other income (expense):
Interest expense....... (138,177) (193,095) (198,274) (51,385) (82,215)
Other.................. (312) 7,966 6,665 2,668 (7,180)
----------- ----------- ----------- ---------- -----------
(138,489) (185,129) (191,609) (48,717) (89,395)
----------- ----------- ----------- ---------- -----------
Income before income
taxes.................. 798,778 954,763 1,908,391 253,140 748,591
Income tax benefit
(provision)............ 208,500 (180,000) (667,937) (86,068) (262,007)
----------- ----------- ----------- ---------- -----------
Net income............... $ 1,007,278 $ 774,763 $ 1,240,454 $ 167,072 $ 486,584
=========== =========== =========== ========== ===========
Net income per share
data:
Primary................ $ 0.39 $ 0.25 $ 0.42 $ 0.04 $ 0.17
=========== =========== =========== ========== ===========
Fully diluted.......... $ 0.30 $ 0.21 $ 0.32 $ 0.04 $ 0.12
=========== =========== =========== ========== ===========
</TABLE>
See accompanying notes.
F-4
<PAGE> 55
SEAMED CORPORATION
STATEMENTS OF SHAREHOLDERS' EQUITY
<TABLE>
<CAPTION>
TOTAL
COMMON STOCK NOTE RETAINED SHAREHOLDERS'
---------------------- RECEIVABLE EARNINGS EQUITY
SHARES AMOUNT FROM OFFICER (DEFICIT) (DEFICIT)
---------- ---------- ------------ ----------- ------------
<S> <C> <C> <C> <C> <C>
Balance, June 30, 1993............... 372,396 $ 735,473 $ -- $(2,603,498) $ (1,868,025)
Stock options exercised............ 122,237 33,822 -- -- 33,822
Net income......................... -- -- -- 1,007,278 1,007,278
--------- -------- -------- ----------- -----------
Balance, June 30, 1994............... 494,633 769,295 -- (1,596,220) (826,925)
Stock options exercised............ 54,331 14,265 -- -- 14,265
Net income......................... -- -- -- 774,763 774,763
--------- -------- -------- ----------- -----------
Balance, June 30, 1995............... 548,964 783,560 -- (821,457) (37,897)
Stock options exercised............ 89,735 28,268 -- -- 28,268
Common stock issued in exchange for
note receivable................. 30,000 75,000 (75,000) -- --
Fractional shares issued due to
reverse stock split............. 8 -- -- -- --
Net income......................... -- -- -- 1,240,454 1,240,454
--------- -------- -------- ----------- -----------
Balance, June 30, 1996............... 668,707 886,828 (75,000) 418,997 1,230,825
Stock options exercised
(unaudited)..................... 4,450 2,470 -- -- 2,470
Net income (unaudited)............. -- -- -- 486,584 486,584
--------- -------- -------- ----------- -----------
Balance, September 30, 1996
(unaudited)........................ 673,157 889,298 (75,000) 905,581 1,719,879
Pro forma accrual of cumulative
dividends on Class A and B
preferred stock (unaudited)..... -- (824,205) -- (905,581) (1,729,786)
Pro forma conversion of convertible
redeemable preferred stock
(unaudited)..................... 2,934,029 5,279,514 -- -- 5,279,514
--------- -------- -------- ----------- -----------
Pro forma balance, September 30, 1996
(unaudited)........................ 3,607,186 $5,344,607 $(75,000) $ -- $ 5,269,607
========= ======== ======== =========== ===========
</TABLE>
See accompanying notes.
F-5
<PAGE> 56
SEAMED CORPORATION
STATEMENTS OF CASH FLOWS
<TABLE>
<CAPTION>
QUARTER ENDED
YEAR ENDED JUNE 30, SEPTEMBER 30,
------------------------------------------- -----------------------
1994 1995 1996 1995 1996
----------- ----------- ----------- --------- ---------
(UNAUDITED)
<S> <C> <C> <C> <C> <C>
OPERATING ACTIVITIES
Net income................. $ 1,007,278 $ 774,763 $ 1,240,454 $ 167,072 $ 486,584
Adjustments to reconcile
net income to net cash
provided by (used in)
operating activities:
Depreciation............. 334,872 421,084 693,752 152,635 241,359
Provision for bad
debts................. 226,830 (25,127) 47,743 (17,500) 25,337
Deferred tax benefit..... (225,000) (54,682) (95,539) (30,203) --
Changes in operating
assets and
liabilities:
Decrease (increase) in
accounts
receivable.......... (1,513,221) (569,079) (2,569,134) (10,508) 303,722
Increase in
inventories......... (1,107,090) (682,803) (2,977,592) (251,355) (527,195)
Increase (decrease) in
accounts payable,
accrued expenses,
and deferred
revenue............. 354,315 801,426 3,402,643 (49,693) (815,303)
Increase in other
assets and prepaid
expenses............ (105,130) (7,615) (38,644) (8,914) (204,283)
----------- ----------- ----------- --------- ---------
Net cash provided by (used
in) operating
activities............... (1,027,146) 657,967 (296,317) (48,466) (489,779)
INVESTING ACTIVITIES
Purchases of equipment..... (875,957) (1,185,267) (1,492,021) (118,344) (311,742)
Purchase of short-term
investments.............. -- (200,000) -- -- --
Proceeds from short-term
investments.............. -- -- 200,000 -- --
----------- ----------- ----------- --------- ---------
Net cash used in investing
activities............... (875,957) (1,385,267) (1,292,021) (118,344) (311,742)
FINANCING ACTIVITIES
Proceeds from stock options
exercised................ 33,822 14,265 28,268 1,250 2,470
Proceeds from sale of
preferred stock.......... -- 1,309,391 -- -- --
Net proceeds from (payments
of) credit line.......... 988,710 (437,185) 1,261,999 171,000 428,755
Proceeds from notes
payable.................. 680,000 750,000 600,000 -- 500,000
Principal payments on notes
payable.................. (390,719) (882,072) (369,400) (72,968) (129,104)
Principal payments on
capital lease
obligations.............. (5,406) (1,368) -- -- --
----------- ----------- ----------- --------- ---------
Net cash provided by
financing activities..... 1,306,407 753,031 1,520,867 99,282 802,121
----------- ----------- ----------- --------- ---------
Net increase (decrease) in
cash..................... (596,696) 25,731 (67,471) (67,528) 600
Cash at beginning of
period................... 641,348 44,652 70,383 70,383 2,912
----------- ----------- ----------- --------- ---------
Cash at end of period...... $ 44,652 $ 70,383 $ 2,912 $ 2,855 $ 3,512
=========== =========== =========== ========= =========
</TABLE>
See accompanying notes.
F-6
<PAGE> 57
SEAMED CORPORATION
NOTES TO FINANCIAL STATEMENTS
(INFORMATION AS OF SEPTEMBER 30, 1996 AND FOR THE
QUARTERS ENDED SEPTEMBER 30, 1995 AND 1996 IS UNAUDITED)
1. ACCOUNTING POLICIES
Description of Business
SeaMED Corporation (the "Company") manufactures advanced durable electronic
medical instruments for medical technology companies, often as part of systems
that also include single-use components. To assist its customers in developing
and commercializing their instruments for manufacture by the Company, the
Company provides a wide range of engineering services and regulatory expertise.
Change in Accounting Period
During fiscal year 1995, the Company changed its fiscal year-end from June
30 to a 52/53-week fiscal year that ends on the Thursday nearest to June 30. For
convenience of presentation, all fiscal periods in these financial statements
are shown as ending on a calendar month-end.
Unaudited Interim Financial Information
The financial information as of September 30, 1996 and for the quarters
ended September 30, 1995 and 1996 is unaudited, but includes all adjustments
(consisting only of normal recurring adjustments) that the Company considers
necessary for a fair presentation of the financial position at such dates and
the operations and cash flows for the periods then ended. Operating results for
the quarter ended September 30, 1996 are not necessarily indicative of results
that may be expected for the entire year.
Use of Estimates
The preparation of financial statements in conformity with generally
accepted accounting principles requires management to make estimates and
assumptions that affect the reported amounts of assets and liabilities and
disclosure of contingent assets and liabilities at the date of the financial
statements and the reported amounts of revenues and expenses during the
reporting period. Actual results could differ from those estimates.
Credit Policies
The Company extends credit to various customers which are primarily in the
medical device industry. Receivables generally are due within 30 days and the
Company generally does not require collateral. The Company maintains reserves
for potential credit losses.
Short-Term Investments
Short-term investments consist of certificates of deposit with a maturity
date of less than one year from June 30, 1995.
Inventories
Inventories are stated at the lower of cost (first-in, first-out) or
market.
F-7
<PAGE> 58
SEAMED CORPORATION
NOTES TO FINANCIAL STATEMENTS (CONTINUED)
(INFORMATION AS OF SEPTEMBER 30, 1996 AND FOR THE
QUARTERS ENDED SEPTEMBER 30, 1995 AND 1996 IS UNAUDITED)
Depreciation
The Company provides for depreciation of furniture, fixtures, equipment and
manufacturing molds over their estimated useful lives of three to eight years
using the straight-line method.
Revenue Recognition
The Company recognizes revenues from contracts to perform engineering
design and product development as costs are incurred for cost-plus contracts, or
based on the percentage-of-completion method for fixed-price contracts. When
estimates indicate a probable loss on a contract, the full amount of such loss
is accrued at that time. The Company generally recognizes revenue from
manufacturing services when the related products are shipped.
Warranty Costs
Warranty reserves are recorded based on historical experience and estimates
of current warranty activity.
Income Taxes
The Company provides for income taxes based on the liability method which
requires the recognition of deferred tax assets and liabilities based on
differences between financial reporting and tax bases of assets and liabilities
measured using enacted tax rates and laws that are expected to be in effect when
the differences are expected to reverse.
Stock Compensation
The Company has elected to follow Accounting Principles Board Opinion No.
25, "Accounting for Stock Issued to Employees," and related interpretations in
accounting for its employee stock options. Generally, stock compensation, if
any, is measured as the difference between the exercise price of a stock option
and the fair market value of the Company's stock at the date of grant, which is
then amortized over the related vesting period.
Net Income Per Share and Pro Forma Net Income Per Share
Except as noted below, historical primary net income per share is based on
the weighted average number of common and common equivalent shares outstanding
during each period. Common equivalent shares include outstanding Class B and C
convertible redeemable preferred stock and outstanding stock options and an
outstanding warrant. Common equivalent shares are not included in the per share
calculations where the effect of their inclusion would be antidilutive, except
that, in accordance with Securities and Exchange Commission requirements, common
and common equivalent shares issued during the 12-month period prior to the
filing of a proposed initial public offering have been included in the
calculation as if they were outstanding for all periods (using the treasury
stock method and an assumed initial public offering price). In addition, net
income is adjusted for the accretion of cumulative preferred stock dividends to
determine earnings applicable to common stock.
Fully diluted net income per share has been computed as described above and
also gives effect to the dilutive effect of the conversion of outstanding Class
A and D convertible redeemable preferred stock net of the effect of the related
cumulative dividends.
F-8
<PAGE> 59
SEAMED CORPORATION
NOTES TO FINANCIAL STATEMENTS (CONTINUED)
(INFORMATION AS OF SEPTEMBER 30, 1996 AND FOR THE
QUARTERS ENDED SEPTEMBER 30, 1995 AND 1996 IS UNAUDITED)
Data used in calculating net income per share information follow:
<TABLE>
<CAPTION>
QUARTER ENDED
YEAR ENDED JUNE 30, SEPTEMBER 30,
------------------------------------ ---------------------
1994 1995 1996 1995 1996
---------- --------- ----------- --------- ---------
<S> <C> <C> <C> <C> <C>
Net income, as reported....... $1,007,278 $ 774,763 $ 1,240,454 $ 167,072 $ 486,584
Accretion of cumulative
preferred stock dividends... (145,850) (203,005) (263,050) (65,763) (65,763)
---------- --------- ---------- --------- ---------
Adjusted income for computing
primary net income
per share................... $ 861,428 $ 571,758 $ 977,404 $ 101,309 $ 420,821
========== ========= ========== ========= =========
Shares used in computing
primary net income
per share................... 2,223,790 2,302,359 2,330,739 2,302,109 2,477,686
========== ========= ========== ========= =========
Shares used in computing fully
diluted net income
per share................... 3,408,860 3,660,549 3,893,243 3,859,579 4,076,402
========== ========= ========== ========= =========
</TABLE>
2. INVENTORIES
Inventories consist of the following:
<TABLE>
<CAPTION>
JUNE 30,
----------------------- SEPTEMBER 30,
1995 1996 1996
---------- ---------- -------------
<S> <C> <C> <C>
Work-in-process.................. $1,602,146 $2,490,710 $ 2,888,094
Purchased and manufactured
parts.......................... 2,117,510 4,206,538 4,336,349
---------- ---------- ----------
$3,719,656 $6,697,248 $ 7,224,443
========== ========== ==========
</TABLE>
3. FIXED ASSETS
Fixed assets consist of the following:
<TABLE>
<CAPTION>
JUNE 30,
----------------------- SEPTEMBER 30,
1995 1996 1996
---------- ---------- -------------
<S> <C> <C> <C>
Equipment, at cost:
Furniture and fixtures......... $ 454,711 $ 514,950 $ 529,600
Equipment...................... 2,489,288 3,657,224 3,937,473
Manufacturing molds............ 514,433 523,999 524,111
Leasehold improvements......... 300,659 554,939 571,670
---------- ---------- ----------
3,759,091 5,251,112 5,562,854
Less accumulated depreciation
and amortization............ 1,902,095 2,595,847 2,837,206
---------- ---------- ----------
$1,856,996 $2,655,265 $ 2,725,648
========== ========== ==========
</TABLE>
F-9
<PAGE> 60
SEAMED CORPORATION
NOTES TO FINANCIAL STATEMENTS (CONTINUED)
(INFORMATION AS OF SEPTEMBER 30, 1996 AND FOR THE
QUARTERS ENDED SEPTEMBER 30, 1995 AND 1996 IS UNAUDITED)
4. ACCRUED EXPENSES AND RESERVES
Accrued expenses and reserves consist of the following:
<TABLE>
<CAPTION>
JUNE 30,
----------------------- SEPTEMBER 30,
1995 1996 1996
---------- ---------- -------------
<S> <C> <C> <C>
Taxes payable.................... $ 150,843 $ 630,036 $ 292,042
Accrued compensation............. 353,585 1,102,565 870,906
Deferred revenue and customer
deposits....................... 494,853 1,015,029 1,065,627
Other accrued expenses........... 215,350 338,146 350,418
Warranty reserve................. 186,411 215,288 244,723
---------- ---------- ----------
$1,401,042 $3,301,064 $ 2,823,716
========== ========== ==========
</TABLE>
5. NOTES PAYABLE
Line of Credit Agreement
The Company has a line of credit agreement with a bank under which the
Company can borrow up to 80% of eligible accounts receivable (less than 60 days
outstanding) up to a maximum of $4,000,000. Borrowings under this agreement are
payable on demand if certain covenants are not met. These covenants include,
among others, requirements that the Company maintain minimum working capital of
$4,000,000, combined net worth, including convertible redeemable preferred
stock, and subordinated debt of $6,000,000, a minimum current ratio of 1.5-to-1,
and a maximum debt-to-equity ratio of 1.5-to-1. The agreement also prohibits the
Company from paying dividends without prior approval of the bank. Borrowings
under this agreement bear interest at the bank's prime rate plus .25% (8.5% at
June 30, 1996) and are secured by receivables and inventories. The agreement is
subject to annual approval and extension by December 1 of each year. Borrowings
outstanding under the line of credit at June 30, 1995 and 1996 were $555,000 and
$1,817,000, respectively. Weighted average borrowings under this agreement were
$627,000, $428,000, $422,000 and $2,000,000 during fiscal years 1994, 1995, and
1996 and the quarter ended September 30, 1996, respectively. Weighted average
interest rates under this agreement were 7.5%, 8.8%, 8.9% and 8.5% during fiscal
years 1994, 1995, and 1996 and the quarter ended September 30, 1996,
respectively.
Long-Term Debt
Long-term debt consists of the following:
<TABLE>
<CAPTION>
JUNE 30,
----------------------- SEPTEMBER 30,
1995 1996 1996
---------- ---------- -------------
<S> <C> <C> <C>
Unsecured subordinated note payable, with monthly payments
of $17,000, including interest, through May 2001. Interest
is adjusted annually on July 1 to 2% over prime, with a
maximum of 10% and a minimum of 7% (10% at June 30,
1996)..................................................... $ 902,390 $ 782,650 $ 750,971
8.5% note payable, secured by equipment, with monthly
payments, including interest, through August 5, 1998...... 614,783 438,456 391,995
8.75% note payable, secured by equipment, with monthly
payments, including interest, through November 5, 1999.... -- 526,666 492,130
8.75% note payable, secured by equipment, with monthly
payments, including interest, through July 5, 2000........ -- -- 483,572
---------- ---------- ----------
1,517,173 1,747,772 2,118,668
Less current portion........................................ 296,067 461,990 583,432
---------- ---------- ----------
$1,221,106 $1,285,782 $ 1,535,236
========== ========== ==========
</TABLE>
F-10
<PAGE> 61
SEAMED CORPORATION
NOTES TO FINANCIAL STATEMENTS (CONTINUED)
(INFORMATION AS OF SEPTEMBER 30, 1996 AND FOR THE
QUARTERS ENDED SEPTEMBER 30, 1995 AND 1996 IS UNAUDITED)
Maturities of long-term debt as of June 30, 1996, including the $500,000
note payable issued in the first quarter of fiscal year 1997, are as follows:
<TABLE>
<S> <C>
1997............................. $ 560,674
1998............................. 624,148
1999............................. 491,460
2000............................. 391,832
2001............................. 179,658
----------
$2,247,772
==========
</TABLE>
Interest of $136,599, $193,095, $198,274, $51,385 and $82,215 was paid in
the fiscal years ended June 30, 1994, 1995, and 1996, and the quarters ended
September 30, 1995 and 1996, respectively.
6. CONVERTIBLE REDEEMABLE PREFERRED STOCK
On January 3, 1995, the Company sold 1,465,000 shares of Class D
convertible redeemable preferred stock at $1.00 per share. These shares are
convertible into common stock at the ratio of 3.75 shares of preferred stock for
each share of common stock. In connection with the Class D preferred stock
offering, the Company also issued a warrant to purchase 39,066 shares of common
stock, with an exercise price of $4.70 per share. The warrant expires December
21, 1999.
If the initial public offering referred to in Note 13 is consummated, all
convertible redeemable preferred stock will convert into 2,934,029 shares of
common stock and the cumulative dividends on Class A and D preferred stock
($1,664,024 and $1,729,786 at June 30, 1996 and September 30, 1996,
respectively) will be declared and paid with a portion of the net proceeds of
the offering. The unaudited pro forma balance sheet and unaudited pro forma
statement of shareholders' equity reflect the assumed conversion of all
preferred stock and the accrual of cumulative preferred stock dividends as of
September 30, 1996.
At June 30, 1996 and September 30, 1996, the Company's convertible
redeemable preferred stock is as follows:
<TABLE>
<CAPTION>
COMMON SHARES
AUTHORIZED OUTSTANDING UPON CONVERSION
---------- ----------- ---------------
<S> <C> <C> <C>
Class A....................................... 1,500,000 1,458,500 1,166,804
Class B....................................... 450,000 450,000 360,016
Class C....................................... 5,100,000 5,082,704 1,016,543
Class D....................................... 2,000,000 1,465,000 390,666
--------- --------- ---------
9,050,000 8,456,204 2,934,029
========= ========= =========
</TABLE>
In the event the offering referred to in Note 13 is not consummated, the
following terms and conditions will continue to apply. Convertible redeemable
preferred stock is convertible into common stock, at the option of the holder,
at various rates, subject to antidilution provisions and any accrued but unpaid
dividends. Unissued shares of common stock are reserved for issuance in the
event of full conversion of all convertible redeemable preferred stock. Subject
to certain conditions, convertible redeemable preferred stock also has mandatory
conversion requirements in the event of a qualified initial public offering of
the Company's common stock.
Each share of convertible redeemable preferred stock has voting rights
equivalent to the number of shares of common stock issuable, if converted. Class
A and D convertible redeemable preferred stock have
F-11
<PAGE> 62
SEAMED CORPORATION
NOTES TO FINANCIAL STATEMENTS (CONTINUED)
(INFORMATION AS OF SEPTEMBER 30, 1996 AND FOR THE
QUARTERS ENDED SEPTEMBER 30, 1995 AND 1996 IS UNAUDITED)
cumulative dividend rights commencing at various dates and payable at $.10 and
$.08 per share, respectively. Each class of convertible redeemable preferred
stock also has preferential rights, in the event of any distribution of assets
upon liquidation of the Company, which are determined as fixed amounts per
share, plus any accrued but unpaid dividends, distributed pro rata on the basis
of liquidation value.
7. SHAREHOLDERS' EQUITY
Reverse Stock Split
Subsequent to year-end, in July 1996, the Company's shareholders approved a
1-for-5 stock split of the common stock, which resulted in an adjustment to the
preferred stock conversion ratio. All share and per share data in the
accompanying financial statements have been retroactively restated to reflect
the reverse stock split.
Stock Option and Incentive Plans
The Company has two stock option and incentive plans (collectively, the
"Plans"), the SeaMED Corporation 1988 Stock Option Plan and the SeaMED
Corporation 1995 Employee Stock Option and Incentive Plan. Under the terms of
the Plans, with respect to incentive stock options and options awarded to
nonemployee directors, the option price may not be less than fair market value
of the common stock at the date of grant. Generally, options granted under the
Plans become exercisable at the rate of 50% after two years, 75% after three
years, and 100% after four years from the date of grant. Certain options granted
under the 1988 plan, however, become exercisable ratably over seven years from
the date of grant. Unexercised options expire on the date set forth in the
optionee's option agreement (generally 10 years), subject to earlier termination
upon the happening of certain events set forth in the 1988 plan (with respect to
options granted under the 1988 plan) and each optionee's option agreement. Stock
options exercised, granted, and canceled during fiscal years 1994, 1995, and
1996 and the quarter ended September 30, 1996, are as follows:
<TABLE>
<CAPTION>
OUTSTANDING OPTIONS
----------------------------------------
NUMBER OF AGGREGATE PRICE PER
SHARES PRICE SHARE
--------- ---------- -----------
<S> <C> <C> <C>
Balance, July 1, 1993.......................... 489,676 $ 175,468 $ .16- .80
Options granted.............................. 87,015 128,758 1.00- 2.20
Options canceled............................. (25,690) (16,860) .50- 1.25
Options exercised............................ (122,237) (33,822) .16- .50
-------- ----------
Balance, June 30, 1994......................... 428,764 253,544 .16- 2.20
Options granted.............................. 89,200 485,500 2.50-10.00
Options canceled............................. (13,252) (10,848) .16- 2.50
Options exercised............................ (54,331) (14,265) .16- .75
-------- ----------
Balance, June 30, 1995......................... 450,381 713,931 .16-10.00
Options granted.............................. 132,824 454,060 2.50- 5.00
Options canceled............................. (8,031) (12,300) .50- 2.50
Options exercised............................ (89,735) (28,268) .16- 1.25
-------- ----------
Balance, June 30, 1996......................... 485,439 1,127,423 .16-10.00
Options granted (unaudited).................. 10,320 51,600 5.00
Options canceled (unaudited)................. (1,110) (2,745) 2.20- 2.50
Options exercised (unaudited)................ (4,450) (2,470) .50- 2.20
-------- ----------
Balance, September 30, 1996 (unaudited)........ 490,199 $1,173,808 $ .16-10.00
======== ==========
</TABLE>
F-12
<PAGE> 63
SEAMED CORPORATION
NOTES TO FINANCIAL STATEMENTS (CONTINUED)
(INFORMATION AS OF SEPTEMBER 30, 1996 AND FOR THE
QUARTERS ENDED SEPTEMBER 30, 1995 AND 1996 IS UNAUDITED)
At June 30, 1996, 223,366 options were exercisable and 105,628 shares were
available for future grant. At September 30, 1996, 228,838 options were
exercisable and 96,418 shares were available for future grant.
Employee Stock Purchase Plan
Subsequent to year-end, in July 1996, the Company's shareholders approved
an employee stock purchase plan to be effective in the event the Company
completes an initial public offering of its common stock. The shareholders
authorized the sale of up to 70,000 shares of common stock over five years
pursuant to the plan.
Shares Reserved for Future Issuance
The following shares of common stock have been reserved for future issuance
as of June 30, 1996, including the stock purchase plan referred to above, and
pursuant to the various other agreements and plans discussed above:
<TABLE>
<S> <C> <C>
Convertible redeemable preferred stock......................... 2,934,029
Common stock purchase warrant.................................. 39,066
Stock purchase plan............................................ 70,000
Stock option and incentive plans:
Options outstanding.......................................... 485,439
Options available for grant.................................. 105,628 591,067
------- ---------
Total common shares reserved for future issuance as of June 30,
1996......................................................... 3,634,162
=========
</TABLE>
8. INCOME TAXES
The income tax benefit (provision) consists of the following:
<TABLE>
<CAPTION>
YEAR ENDED JUNE 30,
------------------------------------
1994 1995 1996
-------- --------- ---------
<S> <C> <C> <C>
Current income tax provision..................... $(16,500) $(234,682) $(763,476)
Deferred income tax benefit...................... 225,000 54,682 95,539
-------- --------- ---------
Income tax benefit (provision)................... $208,500 $(180,000) $(667,937)
======== ========= =========
</TABLE>
The current tax provisions are recorded net of the benefit of utilizing net
operating loss carryforwards and tax credit carryforwards.
F-13
<PAGE> 64
SEAMED CORPORATION
NOTES TO FINANCIAL STATEMENTS (CONTINUED)
(INFORMATION AS OF SEPTEMBER 30, 1996 AND FOR THE
QUARTERS ENDED SEPTEMBER 30, 1995 AND 1996 IS UNAUDITED)
Significant components of the Company's deferred tax assets are as follows:
<TABLE>
<CAPTION>
JUNE 30,
---------------------
1995 1996
-------- --------
<S> <C> <C>
Deferred tax liabilities:
Fixed assets................................................. $(19,511) $(20,337)
Deferred tax assets:
Inventory reserves........................................... 247,780 356,175
Accrued expenses............................................. 111,803 147,712
Bad debt reserves............................................ 69,524 85,757
Tax credit carryforwards..................................... 102,517 --
Other........................................................ 17,569 55,914
-------- --------
Total deferred assets.......................................... 549,193 645,558
-------- --------
Net deferred asset balance..................................... $529,682 $625,221
======== ========
</TABLE>
A reconciliation from the U.S. statutory rate to the effective tax rate is
as follows:
<TABLE>
<CAPTION>
YEAR ENDED JUNE 30,
------------------------
1994 1995 1996
----- ----- ----
<S> <C> <C> <C>
Tax at U.S. statutory rate................................... 34.0% 34.0% 34.0%
Change in valuation allowance................................ (55.5) (26.3) --
Other........................................................ (4.6) 11.2 1.0
----- ----- ----
(26.1)% 18.9% 35.0%
===== ===== ====
</TABLE>
The decrease in the valuation allowance of $443,000 in fiscal year 1994 and
$251,000 in fiscal year 1995 is primarily attributable to the utilization of net
operating loss carryforwards and tax credit carryforwards and related changes in
the estimate of the amount of deferred tax assets to be realizable.
Taxes of $15,000, $28,000, $330,000, $150,000 and $600,000 were paid in the
fiscal years ended June 30, 1994, 1995, and 1996, and the quarters ended
September 30, 1995 and 1996, respectively.
9. REVENUES AND OPERATIONS
During fiscal years 1994, 1995, and 1996, and the quarters ended September
30, 1995 and 1996, 51%, 49%, 41%, 53% and 52%, respectively, of total revenues
were from five customers. Receivables from these five customers represented 41%,
34% and 52% of total accounts receivable at June 30, 1995 and 1996 and September
30, 1996, respectively.
Revenues from customers that represent more than 10% of total revenues are
as follows:
<TABLE>
<CAPTION>
QUARTER ENDED
YEAR ENDED JUNE 30, SEPTEMBER 30,
---------------------------------------- -----------------------
CUSTOMER 1994 1995 1996 1995 1996
---------------------- ---------- ---------- ---------- -------- ----------
<S> <C> <C> <C> <C> <C>
A.................. $2,774,000 $2,278,000 $2,665,000 $739,000 --
B.................. 2,229,000 -- -- 635,000 --
C.................. 1,622,000 -- -- -- --
D.................. -- 1,933,000 -- -- --
E.................. -- -- -- -- $2,522,000
F.................. 1,717,000 2,725,000 3,129,000 558,000 1,039,000
</TABLE>
F-14
<PAGE> 65
SEAMED CORPORATION
NOTES TO FINANCIAL STATEMENTS (CONTINUED)
(INFORMATION AS OF SEPTEMBER 30, 1996 AND FOR THE
QUARTERS ENDED SEPTEMBER 30, 1995 AND 1996 IS UNAUDITED)
10. LEASE COMMITMENTS
The Company currently leases office and production space, and equipment
under noncancelable operating leases. Rental expense under operating lease
agreements for fiscal years 1994, 1995, and 1996 and the quarters ended
September 30, 1995 and 1996 amounted to $358,085, $388,085, $655,079, $152,169
and $240,362, respectively.
In September 1996, the Company entered into lease agreements to occupy
90,000 square feet of production space in two new buildings. The Company will
occupy the first 30,000 square feet on May 1, 1997, the second 30,000 square
feet on February 1, 1998 and the third 30,000 square feet on January 1, 1999.
The lease term is 10 years with two five-year renewal options.
Future minimum lease commitments under noncancelable leases and service
agreements as of June 30, 1996, including the lease for an additional 90,000
square feet, are as follows:
<TABLE>
<S> <C>
1997............................ $ 1,148,312
1998............................ 1,509,818
1999............................ 1,896,476
2000............................ 2,179,100
2001............................ 2,144,291
Thereafter...................... 12,299,185
-----------
$21,177,182
===========
</TABLE>
11. EMPLOYEE BENEFIT PLAN
The Company has a 401(k) savings plan covering substantially all of its
employees. Eligible employees may contribute amounts through payroll deductions.
The Company makes an annual contribution of 37.5% of the employees'
contributions up to 4% of the employees' salary. The 401(k) savings plan expense
was $40,100, $57,672, and $72,000 in fiscal years 1994, 1995, and 1996,
respectively. The Company does not provide other post-retirement benefits.
12. RELATED-PARTY TRANSACTIONS
In January 1995, the Company issued 1,465,000 shares of Class D preferred
stock, which are convertible into an aggregate of 390,666 shares of common stock
at an as-converted price of $3.75 per share. Two directors of the Company
purchased 25,000 and 40,000 shares, respectively, of Class D preferred stock,
which shares are convertible into 6,667 and 10,667 shares of common stock,
respectively. The Company sold such securities pursuant to a preferred stock
purchase agreement on substantially similar terms as were sold to nonaffiliated
purchasers. The terms of the Class D preferred stock provides that all such
shares shall be converted into Common Stock upon the consummation of the
offering referred to in Note 13.
On October 11, 1995, the Company's Chief Executive Officer and President
received a $75,000 loan from the Company, the proceeds of which he used to
purchase 30,000 shares of common stock. The loan is evidenced by an unsecured
promissory note that bears interest at the floating minimum statutory rate set
by the Internal Revenue Service from time to time. This officer may prepay
principal and interest at any time without penalty; unpaid principal and
interest are due on October 11, 2000. As of June 30, 1996, aggregate principal
and accrued interest on this loan was approximately $78,000.
A director of the Company is also a partner in the law firm Preston Gates &
Ellis, the Company's counsel.
F-15
<PAGE> 66
SEAMED CORPORATION
NOTES TO FINANCIAL STATEMENTS (CONTINUED)
(INFORMATION AS OF SEPTEMBER 30, 1996 AND FOR THE
QUARTERS ENDED SEPTEMBER 30, 1995 AND 1996 IS UNAUDITED)
A director of the Company serves as President and Chief Executive Officer
and a director of one of the Company's customers. The Company has provided
engineering and manufacturing services for this customer. The Company recognized
revenues with respect to such services of approximately $1.0 million in fiscal
year 1995 and $355,000 in fiscal year 1996. The Company recognized no revenues
in fiscal year 1994 with respect to such services.
13. SUBSEQUENT EVENTS
Registration Statement and Increase in Authorized Capital Stock
In July 1996, the Company's Board of Directors delegated authority to a
newly formed Executive Committee to authorize filing a Registration Statement
with the Securities and Exchange Commission to permit the Company to sell shares
of its common stock to the public. If the offering is consummated under the
terms presently anticipated, all of the Company's preferred stock will convert
into 2,934,029 shares of common stock and cumulative dividends will be paid from
a portion of the net proceeds of the offering. Also, in July 1996, the Company's
Board of Directors approved an increase in the total number of authorized shares
to 24,050,500, of which 10,000,000 are for common stock and 14,050,500 are for
preferred stock. The respective amounts have been retroactively adjusted on the
accompanying balance sheet and these notes to financial statements.
F-16
<PAGE> 67
(This Page Intentionally Left Blank)
<PAGE> 68
(This Page Intentionally Left Blank)
<PAGE> 69
No dealer, salesperson or other person is authorized to give any information or
to make any representations not contained in this Prospectus in connection with
the offer made by this Prospectus and, if given or made, such information or
representations must not be relied upon as having been authorized by the Company
or the Underwriters. This Prospectus does not constitute an offer to sell or a
solicitation of an offer to buy any of the securities offered hereby by anyone
in any jurisdiction in which such offer or solicitation is not authorized or in
which the person making such offer or solicitation is not qualified to do so or
to anyone to whom it is unlawful to make such an offer or solicitation. Neither
the delivery of this Prospectus nor any sale made hereunder shall, under any
circumstances, create any implication that the affairs of the Company since the
date hereof or the information herein is correct as of any time subsequent to
the date of this Prospectus.
-------------------------------
TABLE OF CONTENTS
<TABLE>
<CAPTION>
Page
----
<S> <C>
Prospectus Summary...................... 3
Risk Factors............................ 5
Use of Proceeds......................... 15
Dividend Policy......................... 15
Dilution................................ 16
Capitalization.......................... 17
Selected Financial Data................. 18
Management's Discussion and Analysis of
Financial Condition and Results of
Operations............................ 19
Business................................ 27
Management.............................. 36
Principal and Selling Shareholders...... 41
Certain Transactions.................... 43
Description of Capital Stock............ 43
Shares Eligible for Future Sale......... 46
Underwriting............................ 47
Legal Matters........................... 48
Experts................................. 48
Additional Information.................. 49
Index to Financial Statements........... F-1
</TABLE>
-------------------------------
Until December 13, 1996 (25 days after the date of this Prospectus), all dealers
effecting transactions in the Common Stock offered hereby, whether or not
participating in this distribution, may be required to deliver a Prospectus.
This is in addition to the obligation of dealers to deliver a Prospectus when
acting as Underwriters and with respect to their unsold allotments or
subscriptions.
1,850,000 SHARES
SeaMED
Corporation
COMMON STOCK
-------------------------
P R O S P E C T U S
-------------------------
PIPER JAFFRAY INC.
NEEDHAM & COMPANY, INC.
November 18, 1996
